Non-small cell lung ⚕️CANCER ❤️NSCLC❤️900 questions+

1. What is Non-Small Cell Lung Cancer (NSCLC)?
NSCLC is the most common type of lung cancer, accounting for about 85% of cases. It includes several subtypes that are grouped together because they behave similarly and are treated differently from small cell lung cancer.

2. How does NSCLC differ from Small Cell Lung Cancer (SCLC)?
NSCLC grows more slowly, is less likely to have spread at diagnosis, and is often amenable to surgery and targeted therapy. SCLC grows rapidly, spreads early, and is treated primarily with chemotherapy and radiation.

3. What percentage of all lung cancers are classified as NSCLC (~85%)?
Approximately 85%.

4. What are the three primary histological subtypes of NSCLC?
Adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.

5. What is Lung Adenocarcinoma?
Adenocarcinoma is the most common subtype, arising from glandular cells, often in the peripheral lung. It is the predominant subtype in never-smokers.

6. What is Squamous Cell Carcinoma of the lung?
Squamous cell carcinoma arises from the flat cells lining the bronchi, typically in central airways, and is strongly associated with smoking.

7. What is Large Cell Carcinoma of the lung?
Large cell carcinoma is a subtype lacking specific features of adenocarcinoma or squamous cell carcinoma; it tends to be peripheral and aggressive.

8. What is Adenosquamous Carcinoma?
A rare subtype containing both adenocarcinoma and squamous cell carcinoma components.

9. What is Sarcomatoid Carcinoma of the lung?
A rare, aggressive subtype with spindle or giant cells, associated with poor prognosis.

10. What is Bronchial Carcinoid Tumor (typical vs. atypical)?
Neuroendocrine tumors; typical carcinoids are low-grade and slow-growing, while atypical carcinoids are more aggressive with higher metastatic potential.

11. What is Adenocarcinoma in Situ (AIS), formerly known as bronchioloalveolar carcinoma (BAC)?
A pre-invasive lesion where malignant cells grow along alveolar walls without invasion; classified as stage 0.

12. What is Minimally Invasive Adenocarcinoma (MIA)?
An early-stage adenocarcinoma with invasion ≤5 mm, with excellent prognosis.

13. What is Invasive Mucinous Adenocarcinoma?
A subtype that produces abundant mucin and often presents as pneumonia-like consolidation.

14. Where in the lungs do adenocarcinomas typically develop (peripheral/outer edges)?
In the peripheral lung tissue, often near the pleura.

15. Where in the lungs do squamous cell carcinomas typically develop (central airways/main bronchi)?
In the central airways, near the main bronchi.

16. What is the cell of origin for lung adenocarcinoma (type II pneumocytes / Clara cells)?
Type II pneumocytes or club (Clara) cells.

17. What is the cell of origin for squamous cell lung carcinoma (bronchial basal epithelial cells)?
Basal cells of the bronchial epithelium.

18. What is the cell of origin for large cell carcinoma?
Likely from pluripotent epithelial cells; exact origin is less defined.

19. How do pathologists distinguish primary NSCLC from metastatic cancer from other organs under the microscope?
Using immunohistochemistry (e.g., TTF-1, napsin A, p40) and clinical history.

20. What is TTF-1 (Thyroid Transcription Factor-1), and why is it positive in lung adenocarcinoma?
TTF-1 is a marker expressed in lung adenocarcinoma; it helps confirm lung origin.

21. What is Napsin A, and how does it help identify lung adenocarcinoma?
Napsin A is a marker highly sensitive for lung adenocarcinoma, used alongside TTF-1.

22. What is p40 (and p63), and why is it used as a definitive marker for squamous cell carcinoma?
p40 and p63 are markers of squamous differentiation, used to confirm squamous cell carcinoma.

23. What is Cytokeratin 5/6 (CK5/6)?
A marker of squamous differentiation, often positive in squamous cell carcinoma.

24. What is Cytokeratin 7 (CK7) vs Cytokeratin 20 (CK20) staining pattern in lung cancer (CK7+/CK20-)?
Lung adenocarcinoma is typically CK7 positive and CK20 negative.

25. What is the difference between poorly differentiated, moderately differentiated, and well-differentiated NSCLC?
Well-differentiated tumors resemble normal tissue and tend to be less aggressive; poorly differentiated tumors look very abnormal and are more aggressive.

26. What are the main growth patterns of invasive adenocarcinoma (lepidic, acinar, papillary, micropapillary, solid)?
These are architectural patterns; lepidic is least aggressive, while micropapillary and solid are high-grade.

27. Why are micropapillary and solid growth patterns classified as high-grade/aggressive adenocarcinoma?
They are associated with higher recurrence rates and worse prognosis.

28. What is Tumor Spread Through Air Spaces (STAS) in NSCLC pathology?
STAS is the spread of tumor cells through air spaces beyond the main tumor margin.

29. Why does the presence of STAS increase the risk of local recurrence after sublobar surgical resection?
STAS can leave residual tumor cells in the remaining lung, increasing recurrence risk.

30. What is a Pancoast tumor (superior sulcus tumor)?
A lung cancer located at the extreme apex of the lung, often invading the chest wall, brachial plexus, and sympathetic nerves.

31. Where is a Pancoast tumor located (extreme apex of the upper lung)?
At the superior sulcus, the very top of the lung.

32. What is Horner Syndrome, and why is it caused by Pancoast tumors pressing on sympathetic nerves?
Horner syndrome results from disruption of the sympathetic chain, causing ptosis, miosis, and anhidrosis.

33. What are the classic signs of Horner Syndrome (ptosis, miosis, anhidrosis)?
Ptosis (drooping eyelid), miosis (constricted pupil), and anhidrosis (lack of sweating).

34. What is Superior Vena Cava (SVC) Syndrome in central NSCLC?
Obstruction of the SVC, causing facial and upper extremity swelling, distended neck veins, and shortness of breath.

35. What causes SVC Syndrome (central tumor compressing the major vein returning blood from the upper body to the heart)?
A central lung tumor or enlarged mediastinal lymph nodes compressing the SVC.

36. What are the symptoms of SVC Syndrome (facial/arm swelling, neck vein distension, shortness of breath)?
Facial and arm swelling, distended neck veins, shortness of breath, and sometimes headache or dizziness.

37. What are Paraneoplastic Syndromes in NSCLC?
Remote effects of cancer not caused by direct invasion or metastasis, such as hypercalcemia, SIADH, and HPOA.

38. What causes hypercalcemia of malignancy in squamous cell lung cancer (PTHrP secretion)?
Squamous cell carcinoma can secrete parathyroid hormone-related protein (PTHrP), causing hypercalcemia.

39. What is Hypertrophic Pulmonary Osteoarthropathy (HPOA) / digital clubbing in NSCLC?
A paraneoplastic syndrome causing digital clubbing, periostitis, and joint pain.

40. What is a solitary pulmonary nodule (SPN)?
A single, well-defined lung opacity ≤3 cm in diameter surrounded by normal lung tissue.

41. What size threshold separates a pulmonary nodule (<3 cm) from a lung mass (>3 cm)?
A nodule is ≤3 cm; a mass is >3 cm.

42. What percentage of incidentally discovered lung nodules turn out to be benign (>90%)?
More than 90% of small incidental nodules are benign.

43. What benign lung conditions mimic NSCLC on CT scans (granulomas, fungal infections, TB, hamartomas)?
Granulomas, fungal infections, tuberculosis, and hamartomas are common benign mimics.

44. What is a ground-glass opacity (GGO) on a chest CT?
A hazy area of increased attenuation that does not obscure underlying bronchial and vascular margins.

45. What is a part-solid lung nodule, and why does it carry a higher malignancy risk than a pure GGO?
A part-solid nodule has both ground-glass and solid components; the solid component increases malignancy risk.

46. What does a spiculated (jagged/starburst) margin on a nodule signify?
A spiculated margin suggests invasive growth and malignancy.

47. What is Pleural Effusion, and how does it relate to NSCLC?
Fluid in the pleural space; it can be malignant in NSCLC and cause shortness of breath.

48. What is Malignant Pleural Effusion (MPE)?
Pleural fluid containing cancer cells, indicating advanced disease.

49. How do NSCLC cells reach the pleural fluid space surrounding the lung?
Cancer cells can invade the pleura directly or spread via lymphatics or blood.

50. What is Pericardial Effusion in advanced NSCLC?
Fluid around the heart, which can occur when lung cancer invades the pericardium.

51. What is lymphangitic carcinomatosis?
Diffuse spread of cancer through pulmonary lymphatics, causing shortness of breath and interstitial patterns on imaging.

52. How does NSCLC spread through the regional mediastinal lymphatic network?
Cancer cells enter lymphatic channels and travel to regional mediastinal lymph nodes.

53. What are mediastinal lymph node stations (e.g., N1 vs N2 vs N3 nodes)?
N1: ipsilateral hilar/peribronchial nodes. N2: ipsilateral mediastinal/subcarinal nodes. N3: contralateral mediastinal, hilar, or supraclavicular nodes.

54. What is skip metastasis in NSCLC lymph node staging?
Spread to N2 nodes without involvement of N1 nodes.

55. Why does NSCLC frequently metastasize to the brain, bones, liver, and adrenal glands?
These organs have rich blood supply and are common sites for hematogenous spread.

56. What is the blood-brain barrier, and why does it complicate treating brain metastases?
The blood-brain barrier restricts drug penetration into the brain, limiting treatment options for brain metastases.

57. What is Leptomeningeal Disease (LMD) in advanced NSCLC?
Spread of cancer to the leptomeninges (membranes covering the brain and spinal cord), causing neurological symptoms.

58. What is the average age of diagnosis for NSCLC (~70 years old)?
The average age at diagnosis is approximately 70 years.

59. Can young adults in their 20s or 30s get NSCLC?
Yes, although it is rare, young adults can develop NSCLC, often with actionable driver mutations.

60. What is the incidence rate of NSCLC in men vs. women?
NSCLC incidence is historically higher in men, but rates in women have been rising, especially in never-smokers.

61. Why are NSCLC rates declining in men while remaining stable or rising in non-smoking women?
Declining smoking rates in men and rising smoking rates or other exposures in women contribute to these trends.

62. Is NSCLC the leading cause of cancer death worldwide?
Lung cancer (including NSCLC) is the leading cause of cancer death worldwide.

63. What is the difference between right lung and left lung anatomy regarding lobes (3 right, 2 left)?
The right lung has three lobes (upper, middle, lower); the left lung has two lobes (upper, lower) and the lingula.

64. Why are NSCLC tumors slightly more common in the right lung than the left lung?
The right lung receives more ventilation and has a larger main bronchus, which may increase exposure to carcinogens.

65. What is the lingula of the left upper lobe?
The lingula is a tongue-like projection of the left upper lobe, analogous to the right middle lobe.

66. What is visceral pleura vs. parietal pleura?
Visceral pleura covers the lung surface; parietal pleura lines the chest wall.

67. What is the pleural cavity?
The potential space between the visceral and parietal pleurae.

68. What is the hilum of the lung?
The region where bronchi, blood vessels, and nerves enter and exit the lung.

69. What is the mediastinum?
The central compartment of the chest containing the heart, great vessels, trachea, esophagus, and lymph nodes.

70. What is atypical adenomatous hyperplasia (AAH) of the lung?
AAH is a pre-invasive lesion that may progress to adenocarcinoma in situ.

71. What is the multi-step progression model of lung adenocarcinoma (AAH → AIS → MIA → Invasive Adenocarcinoma)?
This model describes the stepwise progression from atypical adenomatous hyperplasia to adenocarcinoma in situ, minimally invasive adenocarcinoma, and invasive adenocarcinoma.

72. How fast does NSCLC double in size compared to Small Cell Lung Cancer (SCLC)?
NSCLC has a longer doubling time (often months) compared with SCLC (which doubles in weeks).

73. What is tumor heterogeneity in NSCLC?
The presence of different subpopulations of cancer cells within a single tumor, with varying genetic and biological features.

74. Why do different parts of the same NSCLC tumor harbor different genetic mutations?
Tumor heterogeneity and clonal evolution lead to different mutations in different regions.

75. What is clonal evolution in NSCLC?
The process by which cancer cells accumulate genetic alterations over time, leading to treatment resistance and progression.

76. What is the primary organ site of distant metastasis in lung adenocarcinoma (brain and adrenal glands)?
Brain and adrenal glands are common sites, along with bones and liver.

77. What is the primary organ site of distant metastasis in squamous cell carcinoma (local structures and bones)?
Squamous cell carcinoma tends to spread to local structures and bones.

78. What is a scar carcinoma in lung tissue?
Lung cancer arising in areas of chronic lung scarring from prior infection or fibrosis.

79. How does chronic inflammation from pulmonary fibrosis or past infections promote NSCLC development?
Chronic inflammation causes DNA damage, oxidative stress, and cell proliferation, promoting carcinogenesis.

80. What is the role of tumor-infiltrating lymphocytes (TILs) in the NSCLC microenvironment?
TILs can recognize and attack cancer cells; their presence may predict response to immunotherapy.

81. What is Tumor Mutational Burden (TMB) in NSCLC?
The number of mutations per megabase in tumor DNA; high TMB may predict benefit from immunotherapy.

82. Why do smokers with NSCLC generally have higher TMB than non-smokers?
Tobacco carcinogens cause numerous DNA mutations, leading to higher TMB.

83. How does high TMB correlate with response to immune checkpoint inhibitors?
High TMB is associated with increased likelihood of response to immunotherapy.

84. What is Microsatellite Instability (MSI-H) / Mismatch Repair Deficiency (dMMR) in NSCLC (rare, <1–2%)?
A rare finding in NSCLC associated with response to immunotherapy.

85. What is the genomic difference between smoking-associated NSCLC and non-smoking NSCLC?
Smoking-associated NSCLC has more C:G to A:T transversions and mutations in KRAS, TP53, KEAP1, and STK11; non-smoking NSCLC more often has EGFR, ALK, ROS1, and RET alterations.

86. What somatic gene mutations are linked to tobacco smoking (KRAS, TP53, KEAP1, STK11)?
KRAS, TP53, KEAP1, and STK11 mutations are strongly associated with smoking.

87. What somatic gene alterations are linked to non-smoking NSCLC (EGFR, ALK, ROS1, RET)?
EGFR mutations, ALK fusions, ROS1 fusions, and RET fusions are more common in never-smokers.

88. What is STK11 (LKB1) mutation, and why does it cause resistance to immunotherapy in NSCLC?
STK11 mutations alter metabolism and immune microenvironment, reducing response to immunotherapy.

89. What is KEAP1 mutation, and how does it alter oxidative stress responses in NSCLC?
KEAP1 mutations impair oxidative stress responses, promoting tumor growth and resistance to therapy.

90. What is the significance of co-occurring TP53 mutations with EGFR or ALK alterations?
TP53 co-mutations may worsen prognosis and affect response to targeted therapy.

91. What is MET amplification vs MET exon 14 skipping mutation?
MET amplification is increased MET gene copies; MET exon 14 skipping is a mutation causing MET overactivation.

92. What is HER2 (ERBB2) insertion mutation in NSCLC?
A mutation in the HER2 gene that drives cancer growth and is targetable with HER2-directed therapies.

93. What is a gene fusion / rearrangement in molecular oncology?
A genetic alteration where part of one gene is joined to another, often driving cancer growth (e.g., ALK, ROS1, RET fusions).

94. What is the WHO classification standard for thoracic tumors regarding NSCLC?
The WHO Classification of Thoracic Tumours provides standardized histological and molecular classification.

95. What key pathology term confirms primary invasive lung adenocarcinoma on a biopsy report?
Terms such as “invasive adenocarcinoma” with histologic patterns and immunohistochemical confirmation.

96. Can NSCLC transform into Small Cell Lung Cancer (SCLC) as a mechanism of resistance to targeted therapy?
Yes, transformation to SCLC is a known resistance mechanism, especially in EGFR-mutant NSCLC treated with TKIs.

97. How common is SCLC transformation in EGFR-mutated NSCLC treated with Osimertinib (~5–15%)?
Approximately 5–15%.

98. What key biological markers indicate SCLC transformation (loss of RB1 and TP53)?
Loss of RB1 and TP53 are characteristic of SCLC transformation.

99. Where can oncologists find published international consensus guidelines on NSCLC pathology?
NCCN, WHO Classification of Thoracic Tumours, and IASLC guidelines.

100. What is the single most important biological takeaway regarding NSCLC?
NSCLC is a highly heterogeneous group of diseases defined by distinct histological features and driver mutations, requiring personalized diagnostic and therapeutic approaches.

101. What is biomarker testing / molecular profiling in NSCLC?
Analysis of tumor tissue or blood to identify genetic alterations that guide targeted therapy.

102. Why is comprehensive biomarker testing MANDATORY for all advanced/metastatic NSCLC cases?
It identifies actionable driver mutations and PD-L1 status that determine treatment selection.

103. Why is biomarker testing increasingly recommended for early-stage (Stage IB–III) NSCLC?
To guide adjuvant targeted therapy (e.g., osimertinib for EGFR-mutant, alectinib for ALK-positive) after surgery.

104. What is Next-Generation Sequencing (NGS)?
A high-throughput DNA/RNA sequencing method that tests multiple genes simultaneously.

105. Why is broad multi-gene panel NGS superior to single-gene sequential testing?
It saves time and tissue by identifying multiple actionable alterations in one test.

106. What tissue sample requirements are needed for NGS testing (“Tissue is State”)?
Adequate tumor cellularity and quality are needed; small biopsies may be insufficient.

107. What is Liquid Biopsy (plasma circulating tumor DNA / ctDNA) testing?
A blood test that detects tumor DNA shed into the bloodstream.

108. How does liquid biopsy detect circulating tumor DNA shed into the bloodstream?
It analyzes cell-free DNA in plasma for tumor-specific mutations.

109. When should liquid biopsy be ordered (concurrently with tissue biopsy or when tissue is inadequate/unsafe to sample)?
When tissue is insufficient or when a rapid result is needed; it can complement tissue testing.

110. Can a negative liquid biopsy result rule out a driver mutation (no, false-negative rate is ~15–20% due to low shedding; requires tissue confirmation)?
No, a negative result does not rule out a mutation; tissue testing is still needed.

111. What are Actionable Driver Mutations in NSCLC?
Genetic alterations that can be targeted with specific drugs, such as EGFR, ALK, ROS1, BRAF, KRAS G12C, MET, RET, NTRK, and HER2.

112. What is an EGFR (Epidermal Growth Factor Receptor) mutation?
An activating mutation in the EGFR gene that drives cancer growth and is targetable with EGFR TKIs.

113. What percentage of Western NSCLC patients have EGFR mutations (~15%) vs Asian patients (~50%)?
About 15% in Western populations and up to 50% in Asian populations.

114. What are common classical EGFR mutations (Exon 19 deletion, Exon 21 L858R point mutation)?
Exon 19 deletion and exon 21 L858R are the most common sensitizing EGFR mutations.

115. What percentage of all EGFR mutations do Exon 19 del and L858R represent (~85–90%)?
Approximately 85–90%.

116. What are atypical/uncommon EGFR mutations (Exon 18 G719X, Exon 20 S768I, Exon 21 L861Q)?
Less common EGFR mutations that may have different sensitivity to TKIs.

117. What is an EGFR Exon 20 insertion mutation?
A mutation that is generally resistant to standard EGFR TKIs.

118. Why are EGFR Exon 20 insertion mutations historically resistant to 1st, 2nd, and 3rd generation EGFR TKIs?
Their structural changes reduce drug binding, making them resistant to standard TKIs.

119. What is the EGFR T790M resistance mutation?
A secondary mutation that confers resistance to 1st/2nd generation EGFR TKIs.

120. Why did EGFR T790M develop after treatment with 1st generation TKIs (Erlotinib, Gefitinib)?
Tumor cells acquire T790M to bypass drug inhibition.

121. What is an ALK (Anaplastic Lymphoma Kinase) gene rearrangement/fusion?
A fusion that drives cancer growth and is targetable with ALK inhibitors.

122. What percentage of NSCLC cases harbor an ALK fusion (~3–5%)?
Approximately 3–5%.

123. What is the most common ALK fusion partner gene (EML4-ALK)?
EML4 is the most common fusion partner.

124. What clinical characteristics are typical of ALK-positive NSCLC patients (younger age, never/light smokers, adenocarcinoma)?
Younger age, never or light smokers, and adenocarcinoma histology.

125. What is a KRAS (Kirsten Rat Sarcoma) mutation?
An activating mutation in the KRAS gene that drives cancer growth.

126. What percentage of NSCLC cases harbor a KRAS mutation (~25–30%)?
Approximately 25–30%.

127. What is the most common specific KRAS mutation subtype in NSCLC (KRAS G12C, ~13%)?
KRAS G12C is the most common subtype, accounting for about 13% of NSCLC.

128. Why was KRAS previously considered “undruggable” for decades?
Its structure made it difficult to design drugs that effectively inhibit it.

129. How do modern RAS(ON) and RAS(OFF) inhibitors target KRAS G12C and broad KRAS variants?
They specifically bind to and inhibit mutant KRAS proteins.

130. What is a ROS1 rearrangement/fusion in NSCLC (~1–2% of cases)?
A fusion that drives cancer growth and is targetable with ROS1 inhibitors.

131. What is a BRAF mutation in NSCLC (~2–4% of cases)?
An activating mutation in the BRAF gene, targetable with BRAF/MEK inhibitors.

132. What is the BRAF V600E mutation vs non-V600E BRAF mutations?
V600E is the most common and targetable; non-V600E mutations may have different responses.

133. What is a MET Exon 14 skipping mutation (~3–4% of cases)?
A mutation that causes MET overactivation and is targetable with MET inhibitors.

134. What is MET gene amplification?
Increased copies of the MET gene, which can drive cancer growth and resistance.

135. What is a RET (Rearranged during Transfection) gene fusion (~1–2% of cases)?
A fusion that drives cancer growth and is targetable with RET inhibitors.

136. What are common RET fusion partner genes (KIF5B-RET, CCDC6-RET)?
KIF5B and CCDC6 are common fusion partners.

137. What is an NTRK (Neurotrophic Tyrosine Receptor Kinase 1/2/3) gene fusion (<0.5% of cases)?
A rare fusion that is targetable with NTRK inhibitors.

138. What is a HER2 (ERBB2) mutation in NSCLC (~2–4% of cases)?
A mutation in the HER2 gene, targetable with HER2-directed therapies.

139. What is the difference between HER2 gene mutation, HER2 amplification, and HER2 protein overexpression?
Mutation is a change in the gene sequence; amplification is increased gene copies; overexpression is increased protein.

140. What is PD-L1 (Programmed Death-Ligand 1) expression?
A protein on tumor cells that can suppress immune responses; measured to predict immunotherapy benefit.

141. How is PD-L1 measured in lung tumor tissue (Immunohistochemistry / IHC)?
By immunohistochemistry, reported as Tumor Proportion Score (TPS).

142. What is the Tumor Proportion Score (TPS)?
The percentage of tumor cells expressing PD-L1.

143. What does PD-L1 TPS <1% mean (negative expression)?
Less than 1% of tumor cells express PD-L1.

144. What does PD-L1 TPS 1–49% mean (low/intermediate expression)?
1–49% of tumor cells express PD-L1.

145. What does PD-L1 TPS ≥50% mean (high expression)?
At least 50% of tumor cells express PD-L1.

146. Why does high PD-L1 expression (≥50%) qualify patients for single-agent first-line immunotherapy?
High PD-L1 predicts strong benefit from immunotherapy alone.

147. Can PD-L1 expression change over time or after treatment (yes, it is dynamic)?
Yes, PD-L1 expression can change.

148. Why are oncogene-addicted NSCLCs (e.g., EGFR+, ALK+) often unresponsive to immunotherapy despite high PD-L1 expression?
These tumors often have an immunosuppressive microenvironment and respond better to targeted therapy.

149. Why should immunotherapy NOT be given as first-line monotherapy if an actionable driver mutation is present?
Targeted therapy is more effective and immunotherapy may be less effective or harmful.

150. What severe toxicities occur if targeted TKIs are given immediately after immunotherapy (e.g., severe pneumonitis, hepatitis)?
Severe immune-related toxicities can occur.

151. What is the turn-around time for NGS genomic testing results (typically 10 to 14 business days)?
Usually 10–14 business days.

152. Should systemic treatment for non-squamous NSCLC be delayed until NGS results are back (yes, whenever clinically stable, to avoid wrong therapy selection)?
Yes, when clinically stable, to avoid inappropriate therapy.

153. What is RNA-based NGS vs DNA-based NGS?
RNA-based NGS detects gene fusions more reliably; DNA-based NGS detects mutations and copy number changes.

154. Why is RNA-based NGS superior for detecting gene fusions (ALK, ROS1, RET, NTRK)?
RNA directly reflects expressed fusion transcripts.

155. What is germline testing vs somatic tumor testing?
Germline testing identifies inherited mutations; somatic testing identifies mutations in the tumor.

156. What inherited germline gene mutations raise NSCLC risk (EGFR T790M germline, TP53/Li-Fraumeni, BRCA2, CHEK2)?
Inherited mutations in TP53, BRCA2, CHEK2, and rare EGFR variants can increase risk.

157. What is the role of ctDNA monitoring for Minimal Residual Disease (MRD) after surgery?
It can detect residual disease and predict recurrence risk.

158. Can post-operative ctDNA clearance predict lower recurrence risk in early-stage NSCLC?
Yes, ctDNA clearance is associated with lower recurrence risk.

159. What is a resistance mutation in molecular oncology?
A genetic alteration that allows cancer cells to evade targeted therapy.

160. What secondary resistance mutations develop on Osimertinib (EGFR C797S, MET amplification)?
C797S mutation and MET amplification are common resistance mechanisms.

161. What secondary resistance mutations develop on Lorlatinib or Alectinib (ALK G1202R)?
ALK G1202R and other compound mutations can cause resistance.

162. What is a bypass pathway mechanism of resistance (e.g., MET or HER2 amplification bypassing EGFR blockade)?
Activation of alternative signaling pathways allows cancer cells to survive despite EGFR inhibition.

163. What is histological transformation as a resistance mechanism (NSCLC transforming to SCLC or Squamous Cell)?
Cancer cells change histology to evade treatment.

164. What is ERBB3 / HER3 overexpression in NSCLC?
Overexpression of HER3 can contribute to resistance to EGFR inhibitors.

165. What is TROP2 (Trophoblast Cell Surface Antigen 2) expression in NSCLC?
A protein target for antibody-drug conjugates in NSCLC.

166. What is CEACAM5 expression in NSCLC?
A potential target for antibody-drug conjugates.

167. What is Claudin-6 or Claudin-18.2 in thoracic oncology?
Potential targets for targeted therapies in lung cancer.

168. How do biomarker guidelines differ between Non-Squamous and Squamous Cell NSCLC?
Broad NGS is mandatory for non-squamous; squamous cell may have selective testing unless young or never-smoker.

169. Why is broad NGS testing mandatory for non-squamous NSCLC but selective for squamous cell (unless young/never-smoker)?
Non-squamous NSCLC has a higher prevalence of actionable mutations.

170. What is an indeterminate or variant of uncertain significance (VUS) NGS result?
A genetic variant with unknown clinical significance.

171. How do molecular tumor boards interpret complex or rare NGS genomic variants?
They integrate clinical, pathological, and genomic data to guide treatment.

172. What is the cost and insurance coverage landscape for comprehensive NGS testing?
Coverage varies; many insurers cover NGS for advanced cancer.

173. What is Medicare National Coverage Determination (NCD) for NGS in advanced cancer?
Medicare covers NGS for advanced cancer under specific conditions.

174. How do assistance programs help uninsured patients access NGS molecular profiling?
Financial assistance programs and manufacturer programs may help.

175. What is reflex biomarker testing in pathology departments?
Automatic testing of tumor tissue for biomarkers without a separate order.

176. Why does reflex testing by pathologists speed up treatment decisions compared to oncologist-ordered testing?
It reduces delays by initiating testing immediately after diagnosis.

177. What is tissue stewardship in small biopsy specimens?
Careful management of limited tissue to ensure adequate material for diagnosis and molecular testing.

178. How do pathologists preserve tissue during initial workup to ensure enough remains for NGS?
By minimizing unnecessary tests and using appropriate sectioning.

179. What is cell-free DNA (cfDNA) vs circulating tumor DNA (ctDNA)?
cfDNA is all free DNA in blood; ctDNA is the tumor-derived fraction.

180. What is shedding rate in liquid biopsy (why central nervous system or small abdominal metastases shed less ctDNA)?
Tumors in certain locations shed less DNA into the bloodstream, reducing sensitivity.

181. What is clonal hematopoiesis of indeterminate potential (CHIP), and how can it cause false-positive blood NGS results (e.g., KRAS/TP53 in blood cells)?
CHIP is age-related acquisition of mutations in blood cells, which can be mistaken for tumor mutations.

182. How do bioinformatic pipelines filter out CHIP variants from true tumor ctDNA?
By comparing with matched white blood cell sequencing.

183. What key biomarker details must be included on an NSCLC molecular pathology report?
Histology, mutation results (with variant allele frequency), PD-L1 TPS, and methodology.

184. What questions should a patient ask their oncologist about their biomarker test?
Ask about which tests were performed, results, and treatment implications.

185. “Was broad NGS testing performed on my tumor?”
Correct.

186. “Do I have an EGFR, ALK, KRAS, ROS1, RET, or other driver mutation?”
Correct.

187. “What is my exact PD-L1 expression percentage?”
Correct.

188. “Was testing performed using tissue, liquid biopsy, or both?”
Correct.

189. “Are my results back before we start systemic treatment?”
Correct.

190. Why is re-biopsy recommended at the time of disease progression on targeted therapy?
To identify resistance mechanisms and guide next-line therapy.

191. How does identifying secondary resistance mechanisms guide second-line precision treatment?
It allows selection of therapies targeting the resistance pathway.

192. What online databases classify actionable genomic variants in lung cancer (e.g., My Cancer Genome, OncoKB)?
My Cancer Genome, OncoKB, and CIViC.

193. How do patient advocacy groups support specific biomarker communities (e.g., EGFR Resisters, ALK Positive, ROS1ders, KRAS Kickers)?
They provide education, support, and research advocacy.

194. What is the future of multi-omic testing (combining genomics, transcriptomics, and proteomics) in NSCLC?
It will enable more comprehensive and personalized treatment selection.

195. How is AI/Machine Learning analyzing pathology slides to predict driver mutations directly from H&E stains?
AI can identify patterns associated with mutations from routine slides.

196. What is the global availability of NGS testing in low- and middle-income countries?
Limited, but improving with capacity-building efforts.

197. How are rapid PCR-based blood tests used where full NGS is unavailable?
They provide faster, targeted mutation detection.

198. Where can oncologists access updated NCCN Guidelines for Biomarker Testing in NSCLC?
NCCN website.

199. What summary roadmap defines modern precision NSCLC diagnosis?
Histology confirmation + Broad NGS driver mutation panel + PD-L1 IHC testing = Personalized Treatment Plan.

200. What is the key takeaway about biomarker testing in NSCLC?
Comprehensive biomarker testing is essential for guiding personalized treatment and improving outcomes.

201. What are the early symptoms of NSCLC?
Persistent cough, hemoptysis, shortness of breath, chest pain, and unexplained weight loss.

202. Can NSCLC exist without any symptoms in its early stages?
Yes, early-stage NSCLC is often asymptomatic.

203. What percentage of early-stage NSCLC cases are completely asymptomatic (~50–70%)?
About 50–70%.

204. What is the most common presenting symptom of NSCLC (persistent cough)?
Persistent cough.

205. How does a “lung cancer cough” feel or differ from a standard cold or smoker’s cough?
It is persistent, often worsening, and may be associated with hemoptysis.

206. What does a change in a chronic smoker’s cough (pitch, frequency, severity) indicate?
It warrants evaluation for possible lung cancer.

207. What is hemoptysis (coughing up blood)?
Coughing up blood or blood-streaked sputum.

208. How much blood in sputum warrants urgent medical evaluation (even tiny specks or streaks require investigation)?
Any hemoptysis should be evaluated.

209. What causes coughing up blood in NSCLC (tumor erosion into bronchial blood vessels)?
Tumor erosion into bronchial vessels.

210. What is shortness of breath (dyspnea) in NSCLC?
Difficulty breathing or breathlessness.

211. What causes shortness of breath in NSCLC (airway blockage, pleural effusion, loss of functional lung tissue)?
Airway obstruction, pleural effusion, or loss of lung tissue.

212. What causes chest pain in NSCLC (tumor invasion into chest wall, pleura, or ribs)?
Tumor invasion into chest wall, pleura, or ribs.

213. What does chest pain from NSCLC feel like (sharp, dull, aching, or worse with deep breathing/coughing)?
It can be sharp, dull, aching, or pleuritic.

214. Can NSCLC cause unexplained back pain or shoulder pain?
Yes, especially with Pancoast tumors or bone metastases.

215. What causes unexplained weight loss in NSCLC (cancer cachexia, altered metabolic rate)?
Cancer cachexia and altered metabolism.

216. What is loss of appetite (anorexia) in NSCLC patients?
Decreased appetite, often due to cancer-related factors.

217. What causes severe, persistent fatigue in NSCLC?
Cancer-related fatigue from the disease and treatment.

218. What causes hoarseness or voice changes in NSCLC (tumor pressing on the recurrent laryngeal nerve)?
Recurrent laryngeal nerve involvement.

219. What is wheezing or stridor in NSCLC?
Noisy breathing due to airway narrowing.

220. What causes recurrent chest infections like pneumonia or bronchitis that refuse to clear?
Airway obstruction by tumor.

221. Why does a tumor blocking a bronchus cause post-obstructive pneumonia behind the blockage?
Retained secretions behind the obstruction lead to infection.

222. What is fingernail clubbing (digital clubbing / Schamroth’s sign)?
Bulbous enlargement of the fingertips with nail changes.

223. What does fingernail clubbing look like (softening of nail beds, curving down of nails, bulbous fingertips)?
Softening of nail beds, increased curvature, and bulbous fingertips.

224. Can NSCLC cause difficulty swallowing (dysphagia)?
Yes, if mediastinal nodes compress the esophagus.

225. What causes swallowing difficulty in NSCLC (mediastinal lymph nodes pressing on the esophagus)?
Esophageal compression by tumor or nodes.

226. What causes swelling in the face, neck, or upper arms (SVC Syndrome)?
Superior vena cava obstruction.

227. What symptoms indicate NSCLC has spread to the brain (headaches, seizures, vision changes, confusion, weakness on one side)?
Headaches, seizures, vision changes, confusion, and focal weakness.

228. What symptoms indicate NSCLC has spread to the bones (deep, aching bone pain, pathological fractures, spinal cord compression)?
Bone pain, fractures, and spinal cord compression.

229. What is spinal cord compression from metastatic NSCLC, and why is it a medical emergency?
Tumor pressing on the spinal cord; requires urgent treatment to prevent paralysis.

230. What symptoms signal spinal cord compression (sudden back pain, leg weakness, numbness, loss of bowel/bladder control)?
Back pain, leg weakness, numbness, and bowel/bladder dysfunction.

231. What symptoms indicate NSCLC has spread to the liver (jaundice, right upper abdominal pain, abdominal fluid/ascites)?
Jaundice, right upper quadrant pain, and ascites.

232. What symptoms indicate NSCLC has spread to the adrenal glands (often asymptomatic, detected on staging scans)?
Often asymptomatic, detected on imaging.

233. Can NSCLC cause swollen lymph nodes in the neck or above the collarbone (supraclavicular lymphadenopathy)?
Yes.

234. What is a Virchow’s node in advanced thoracic malignancy?
A supraclavicular lymph node, often on the left, associated with abdominal/thoracic malignancy.

235. What symptoms indicate hypercalcemia (confusion, excessive thirst, frequent urination, constipation, nausea)?
Confusion, thirst, frequent urination, constipation, and nausea.

236. What symptoms indicate Syndrome of Inappropriate Antidiuretic Hormone (SIADH) (hyponatremia, muscle weakness, confusion)?
Hyponatremia, weakness, and confusion.

237. What symptoms indicate Horner Syndrome (drooping eyelid, small pupil, lack of face sweating on one side)?
Ptosis, miosis, and anhidrosis.

238. What is Pancoast syndrome arm pain (severe pain shooting down inner arm along ulnar nerve distribution)?
Severe pain radiating down the inner arm.

239. Can NSCLC cause unexplained blood clots (Deep Vein Thrombosis / DVT or Pulmonary Embolism / PE)?
Yes, cancer-associated hypercoagulability.

240. What is Trousseau syndrome of hypercoagulability in cancer?
Migratory thrombophlebitis associated with malignancy.

241. How does shortness of breath from PE differ from shortness of breath caused by the lung tumor itself?
PE causes sudden severe dyspnea, often with chest pain.

242. Can NSCLC cause night sweats or unexplained low-grade fever?
Yes.

243. Why do tumors produce low-grade fever (tumor necrosis, cytokine release, secondary infection)?
Tumor necrosis and cytokine release.

244. How do NSCLC symptoms differ between men and women?
Women more often present with adenocarcinoma and dyspnea/fatigue; men more often with squamous cell and cough/hemoptysis.

245. Why are women more likely to present with peripheral adenocarcinomas (causing dyspnea/fatigue rather than cough/hemoptysis)?
Peripheral tumors cause fewer airway symptoms.

246. Why are heavy smokers more likely to present with central squamous cell carcinoma (causing cough, hemoptysis, airway obstruction)?
Central tumors cause airway symptoms earlier.

247. Can NSCLC cause anemia (pale skin, dizziness, fast heart rate)?
Yes.

248. What physical exam signs does a physician check for when suspecting NSCLC?
Diminished breath sounds, dullness to percussion, lymphadenopathy, and clubbing.

249. What do diminished or absent breath sounds on one side indicate (atelectasis, pleural effusion)?
Atelectasis or pleural effusion.

250. What is dullness to percussion during chest examination?
A sign of pleural effusion or consolidation.

251. What is tracheal deviation, and when does it occur in severe thoracic conditions?
Tracheal shift due to large effusion or atelectasis.

252. What is subcutaneous emphysema / crepitus?
Air in subcutaneous tissue, causing crackling sensation.

253. Can a persistent cough lasting more than 3 weeks be an early sign of NSCLC?
Yes.

254. When should a persistent cough trigger an immediate chest X-ray or CT scan?
If it lasts more than 3 weeks or is associated with hemoptysis or weight loss.

255. What red flag symptoms require urgent emergency department evaluation?
Coughing up more than a teaspoon of blood, sudden severe dyspnea, sudden leg weakness, severe headache with confusion.

256. Coughing up more than a teaspoon of blood, sudden severe dyspnea, sudden leg weakness, severe headache with confusion.
Correct.

257. How fast do NSCLC symptoms develop (typically over several months to a year)?
Often over months.

258. Can NSCLC present as unexplained abdominal pain or nausea (due to liver metastasis or hypercalcemia)?
Yes.

259. Can NSCLC present as cognitive decline or dementia-like symptoms in older adults (due to brain metastases)?
Yes.

260. Can NSCLC present as persistent shoulder pain mistaken for rotator cuff injury or arthritis?
Yes, especially Pancoast tumors.

261. What percentage of Pancoast tumors are initially misdiagnosed as cervical spine or shoulder orthopedic issues (~75%)?
About 75%.

262. How long is the average diagnostic delay from first symptom to NSCLC diagnosis (typically 2 to 6 months)?
2–6 months.

263. Why do patients delay seeking medical care for early NSCLC symptoms (attributing cough to smoking/aging, fear, lack of awareness)?
Attribution to smoking/aging, fear, and lack of awareness.

264. Why do doctors sometimes delay ordering CT scans for non-smokers presenting with persistent cough?
Low suspicion due to non-smoking status.

265. Can NSCLC cause chest tightness or inability to take a full deep breath?
Yes.

266. What is pleuritic chest pain (sharp pain during inhalation/coughing caused by pleural irritation)?
Sharp pain worsened by breathing or coughing.

267. Can NSCLC cause skin nodules (cutaneous metastases – rare)?
Yes, though rare.

268. What do cutaneous NSCLC metastases look like (painless, firm, reddish or skin-colored nodules)?
Painless, firm nodules.

269. Can NSCLC cause eye symptoms (blurred vision, drooping lid, unequal pupils)?
Yes, with Horner syndrome or brain metastases.

270. What symptoms occur when NSCLC invades the sympathetic trunk nerves?
Horner syndrome.

271. How do symptoms of central airway tumors differ from peripheral lung tumors?
Central tumors cause cough, hemoptysis, and obstruction; peripheral tumors are often silent until advanced.

272. Why do peripheral lung tumors remain clinically silent longer than central tumors?
They do not obstruct airways early.

273. What symptom combination is most predictive of lung cancer in high-risk individuals (cough + hemoptysis + weight loss)?
Cough, hemoptysis, and weight loss.

274. How does NSCLC presentation differ in young adults compared to elderly patients?
Young adults more often have driver mutations and adenocarcinoma.

275. What physical changes signal that NSCLC treatment is working (eased breathing, clearing cough, weight gain)?
Improved breathing, reduced cough, and weight gain.

276. What symptoms indicate treatment side effects vs. disease progression?
New or worsening symptoms should be evaluated.

277. What warning signs should prompt an unscheduled visit between oncology appointments?
New symptoms or worsening of existing symptoms.

278. What physical changes occur as cancer cachexia advances?
Muscle wasting and weight loss.

279. What symptoms indicate diaphragmatic paralysis (tumor invading phrenic nerve causing paradoxical abdominal breathing)?
Paradoxical abdominal breathing.

280. Can NSCLC cause persistent hiccups (phrenic nerve irritation)?
Yes.

281. What questions will a doctor ask during a clinical evaluation for suspected NSCLC?
Smoking history, symptoms, occupational exposures, and family history.

282. How do doctors document pack-years of smoking history?
Packs per day multiplied by years smoked.

283. How is pack-years calculated (packs smoked per day × number of years smoked)?
Correct.

284. What is the clinical significance of a 20 pack-year vs 30 pack-year history?
Higher pack-years increase risk and eligibility for screening.

285. How do doctors document environmental or occupational exposure history?
Detailed occupational and exposure history.

286. What is the role of patient-reported outcomes (PROs) in tracking NSCLC symptoms?
They help monitor symptoms and treatment effects.

287. How do digital symptom tracking apps help patients record daily pain, fatigue, and breathlessness?
They provide structured symptom data.

288. What visual guides or infographics help patients recognize early warning signs?
Educational materials from cancer organizations.

289. What role do primary care doctors and pulmonologists play in early symptom identification?
They are often the first point of contact.

290. How does public education about non-smoker lung cancer symptoms reduce diagnostic delays?
It increases awareness and prompts earlier evaluation.

291. What is the single most important clinical message regarding NSCLC symptoms?
Any new, persistent, or changing chest symptom lasting over 3 weeks warrants diagnostic imaging—regardless of smoking history.

292. Any new, persistent, or changing chest symptom lasting over 3 weeks warrants diagnostic imaging—regardless of smoking history.
Correct.

293. Where can patients access validated symptom checklists online?
Cancer organization websites.

294. How do multidisciplinary lung cancer clinics streamline symptom evaluation?
They coordinate care among specialists.

295. Can NSCLC cause swollen feet or leg edema (DVT or vena cava pressure)?
Yes.

296. What physical exam findings distinguish pleural effusion from lobar consolidation?
Dullness to percussion and decreased breath sounds suggest effusion.

297. How does acute dyspnea from pneumothorax present after lung biopsy?
Sudden shortness of breath and chest pain.

298. What physical signs indicate pericardial tamponade (Beck’s triad: low BP, muffled heart sounds, distended neck veins)?
Beck’s triad.

299. What step-by-step actions should a patient take if they develop suspicious symptoms?
Schedule evaluation, request imaging if persistent, and advocate for answers.

300. Schedule a medical evaluation, request a chest CT if symptoms persist >3 weeks, and advocate for clear diagnostic answers.
Correct.

301. What causes NSCLC?
A combination of genetic and environmental factors, primarily tobacco smoking.

302. What percentage of NSCLC cases are linked to cigarette smoking (~80–85%)?
About 80–85%.

303. How much does cigarette smoking increase the risk of NSCLC (~15 to 30 times higher risk)?
15–30 times higher risk.

304. How do tobacco smoke carcinogens damage DNA in bronchial lung cells?
By forming DNA adducts and causing mutations.

305. What specific carcinogens are present in tobacco smoke (PAHs, nitrosamines like NNK, benzene, polonium-210)?
PAHs, NNK, benzene, and polonium-210.

306. Does cigar or pipe smoking cause NSCLC?
Yes.

307. Does vaping / e-cigarette usage cause NSCLC?
Evidence is still evolving; long-term risks are not fully known.

308. What are the long-term cellular effects of e-cigarette vapor on bronchial epithelial tissue?
Oxidative stress and DNA damage.

309. Does hookah / waterpipe smoking cause NSCLC?
Yes.

310. Does smoking marijuana / cannabis cause NSCLC?
Chronic heavy use may increase risk.

311. What is secondhand smoke (environmental tobacco smoke / ETS)?
Smoke exhaled by smokers and sidestream smoke.

312. How much does secondhand smoke increase NSCLC risk in non-smokers (~20–30% increased risk)?
20–30% increased risk.

313. How many non-smokers die from secondhand smoke-induced lung cancer annually in the US (~7,300 deaths)?
About 7,300 deaths.

314. What is thirdhand smoke (residual nicotine and toxic chemicals left on indoor surfaces/clothing)?
Residual tobacco smoke contaminants.

315. What is Radon gas, and why is it the #1 cause of NSCLC in non-smokers?
A radioactive gas from soil and rock; leading cause in never-smokers.

316. How does radon gas enter homes (foundation cracks, basement floors, well water)?
Through cracks and openings.

317. How does decay of radon gas emit alpha particles that damage lung cell DNA?
Alpha particles damage DNA.

318. What radon level in pCi/L (picocuries per liter) requires home mitigation (EPA action level: 4.0 pCi/L or higher)?
4.0 pCi/L or higher.

319. How can homeowners test their houses for radon gas?
With radon test kits.

320. What is Asbestos, and how does asbestos exposure cause NSCLC and mesothelioma?
Asbestos fibers cause chronic inflammation and DNA damage.

321. How do microscopic asbestos fibers get trapped permanently in lung tissue?
They cannot be cleared.

322. What is the synergistic effect between asbestos exposure and cigarette smoking (multiplies NSCLC risk by up to 50 times)?
Combined exposure greatly increases risk.

323. What occupational exposures raise NSCLC risk (silica dust, arsenic, beryllium, cadmium, chromium, nickel, diesel exhaust)?
These and others.

324. What industries carry higher occupational risks for NSCLC (construction, mining, shipbuilding, chemical manufacturing, auto mechanics)?
These industries.

325. What is Outdoor Air Pollution / Fine Particulate Matter (PM2.5)?
Fine particles that penetrate deep into the lungs.

326. How does WHO / IARC classify outdoor air pollution as a Group 1 human carcinogen?
As carcinogenic to humans.

327. How does long-term exposure to high PM2.5 levels trigger lung inflammation and promote EGFR-mutated NSCLC?
Chronic inflammation and oxidative stress.

328. What is indoor air pollution from cooking fumes / coal burning (unvented stoves, biomass fuels)?
Indoor smoke from cooking and heating.

329. Why is indoor cooking oil fume exposure a major risk factor for non-smoking women in parts of Asia?
High-temperature cooking oils release carcinogens.

330. Is NSCLC hereditary?
Most cases are not hereditary, but family history increases risk.

331. Does having a first-degree relative (parent, sibling, child) with lung cancer double your personal risk?
Yes, approximately.

332. What inherited gene mutations raise NSCLC susceptibility (EGFR T790M germline, TP53/Li-Fraumeni, BRCA2, CHEK2)?
TP53, BRCA2, CHEK2, and rare EGFR variants.

333. What is Polygenic Risk Score (PRS) in lung cancer prediction?
A score combining many genetic variants to estimate risk.

334. Does a prior personal history of tuberculosis (TB) or pulmonary fibrosis raise NSCLC risk?
Yes.

335. What is scar carcinoma in lung tissue?
Cancer arising in scarred lung tissue.

336. Does Chronic Obstructive Pulmonary Disease (COPD) or emphysema raise NSCLC risk independent of smoking?
Yes.

337. How much does having COPD increase NSCLC risk (2 to 4 times higher risk)?
2–4 times higher.

338. Does idiopathic pulmonary fibrosis (IPF) raise NSCLC risk?
Yes.

339. Does asthma raise NSCLC risk?
Evidence is mixed.

340. Does prior chest radiation therapy (e.g., for Hodgkin lymphoma or breast cancer) raise NSCLC risk?
Yes.

341. What is the latency period between carcinogen exposure and NSCLC development (typically 15 to 40 years)?
15–40 years.

342. Does quitting smoking lower your risk of developing NSCLC?
Yes.

343. How fast does NSCLC risk decline after quitting smoking (drops by 50% after 10 years of cessation)?
About 50% after 10 years.

344. Can former smokers who quit 20+ years ago still get NSCLC?
Yes.

345. Why does DNA damage from past smoking persist in lung cells decades after quitting?
Mutations persist in stem cells.

346. What smoking cessation strategies are most effective (combination of NRT/Varenicline/Cytisine + behavioral counseling)?
Combination therapy.

347. Does age at starting smoking impact lifetime risk (starting as a teenager significantly raises risk)?
Yes.

348. Does smoking menthol cigarettes carry a higher risk than regular cigarettes?
May increase dependence; risk evidence is not definitive.

349. Does smoking “light” or “low-tar” cigarettes lower NSCLC risk (no, changed inhalation depth led to more peripheral adenocarcinomas)?
No.

350. How has the shift in cigarette design altered the predominant histology of NSCLC over decades (from squamous cell to adenocarcinoma)?
Deeper inhalation led to more peripheral adenocarcinomas.

351. What percentage of NSCLC patients have NEVER smoked (~10–20% in US/Europe, up to 30–40% in Asia)?
10–20% in US/Europe; up to 30–40% in Asia.

352. If “lung cancer in never-smokers” were classified separately, where would it rank in cancer deaths (5th leading cause of cancer death worldwide)?
5th leading cause.

353. What are the predominant features of NSCLC in never-smokers (female, adenocarcinoma, younger age, targetable driver mutations)?
Female, adenocarcinoma, younger age, and driver mutations.

354. Does diet play a direct role in preventing or causing NSCLC?
Diet plays a modest role.

355. High-dose Beta-Carotene supplements raise lung cancer risk in active smokers (CARET and ATBC trials).
Correct.

356. Does a diet high in fruits and vegetables lower NSCLC risk (mild protective association due to antioxidants/fiber)?
Mild protective association.

357. Does alcohol consumption raise NSCLC risk?
Heavy alcohol may modestly increase risk.

358. Does physical exercise lower NSCLC risk?
Regular exercise may modestly lower risk.

359. Does chronic emotional stress cause NSCLC?
No direct causal link.

360. Can physical trauma or chest injury cause NSCLC?
No.

361. Fact: Physical trauma or blunt force chest injury CANNOT cause cancer.
Correct.

362. Does wearing an underwire bra cause lung cancer (no, completely false myth)?
No.

363. Does living at high altitude impact NSCLC risk (unproven)?
Unproven.

364. Does exposure to mold or mildew cause NSCLC?
No.

365. Does exposure to fiberglass or mineral wool cause NSCLC?
Not classified as carcinogens.

366. Does exposure to diesel exhaust fumes raise NSCLC risk (classified as Group 1 carcinogen by IARC)?
Yes.

367. What OSHA workplace safety regulations protect workers from lung carcinogens?
OSHA sets exposure limits and requires PPE.

368. How do personal protective equipment (PPE) and N95/respirators reduce occupational hazard inhalation?
By filtering airborne particles.

369. What EPA guidelines govern home radon testing and abatement?
EPA recommends testing and mitigation if ≥4 pCi/L.

370. How does a sub-slab depressurization system mitigate high home radon levels?
It vents radon from beneath the foundation.

371. Does air purifier / HEPA filter usage lower NSCLC risk from indoor air pollution?
May reduce exposure but not proven to lower cancer risk.

372. Does green tea consumption prevent NSCLC (inconclusive evidence)?
Inconclusive.

373. Can Vitamin D deficiency raise NSCLC risk?
Association exists but causality is not established.

374. Are there chemoprevention drugs approved to prevent NSCLC in high-risk individuals (currently none approved)?
None approved.

375. What clinical trials are investigating chemoprevention agents for bronchial dysplasia?
Ongoing trials.

376. How do public smoking bans in restaurants/workplaces lower population secondhand smoke exposure?
They reduce exposure.

377. How does raising tobacco taxes impact youth smoking initiation rates?
They reduce initiation.

378. What role do anti-vaping public health campaigns play in adolescent lung health?
They aim to prevent initiation.

379. Why is stigma associated with smoking harmful to NSCLC patients?
It causes shame, delays diagnosis, and reduces support.

380. How does lung cancer stigma delay diagnosis and reduce research funding compared to other cancers?
Stigma reduces awareness and funding.

381. What message helps combat lung cancer stigma (“Anyone with lungs can get lung cancer”)?
That anyone with lungs can get lung cancer.

382. Does human papillomavirus (HPV) infection cause NSCLC (controversial, weak association in select cases)?
Not established.

383. Does HIV infection raise NSCLC risk (yes, HIV-positive individuals have higher risk due to immune dysfunction and smoking rates)?
Yes.

384. Does immunosuppressive therapy (e.g., after organ transplant) raise NSCLC risk?
Yes.

385. How do systemic autoimmune diseases (scleroderma, rheumatoid arthritis, lupus) impact NSCLC risk?
Some increase risk, especially with lung involvement.

386. What is the impact of socio-economic status and health disparities on NSCLC incidence and outcomes?
Lower SES is associated with higher incidence and worse outcomes.

387. Why do Black men experience higher rates of NSCLC at lower smoking levels than white men?
Multifactorial, including genetics, environment, and access to care.

388. What modifiable risk factors account for the majority of preventable NSCLCs (smoking, radon, occupational exposure, air pollution)?
Smoking, radon, occupational exposures, and air pollution.

389. What non-modifiable risk factors remain (age, genetics, female sex, underlying lung diseases)?
Age, genetics, and underlying lung diseases.

390. What steps can a high-risk individual take today to lower personal risk?
Quit smoking, test for radon, avoid secondhand smoke, and use PPE.

391. Quit smoking, test home for radon, avoid secondhand smoke, wear occupational PPE, eat a balanced diet.
Correct.

392. How does combining smoking cessation with annual CT screening offer the highest survival benefit?
Cessation lowers risk and screening detects early cancer.

393. Where can homeowners buy certified low-cost radon test kits?
Hardware stores and online retailers.

394. What free resources help individuals quit smoking (1-800-QUIT-NOW, smokefree.gov)?
1-800-QUIT-NOW and smokefree.gov.

395. What workplace safety rights protect employees exposed to airborne hazards?
OSHA rights.

396. How do air quality index (AQI) apps help vulnerable individuals limit outdoor PM2.5 exposure?
They provide real-time air quality data.

397. What scientific consensus exists regarding electronic cigarettes vs traditional tobacco harm reduction?
E-cigarettes may be less harmful but are not harmless.

398. What key risk factor questions should you discuss with your primary care provider?
Smoking, radon, occupational exposures, and family history.

399. Where can patients view published IARC carcinogen classifications for lung hazards?
IARC Monographs website.

400. What is the ultimate summary on NSCLC prevention (smoking cessation + radon testing + screening saves thousands of lives daily)?
Smoking cessation, radon testing, and screening save lives.

401. What is lung cancer screening?
Testing for lung cancer in high-risk individuals before symptoms appear.

402. What imaging scan is used for lung cancer screening?
Low-dose computed tomography (LDCT).

403. What is a Low-Dose Computed Tomography (LDCT) scan?
A CT scan using low radiation to detect lung nodules.

404. How does LDCT differ from a standard chest CT scan (uses 80–90% less radiation while producing high-resolution lung images)?
Uses much less radiation.

405. Why are standard chest X-rays NOT recommended for lung cancer screening?
They are not sensitive enough to detect early cancer.

406. What landmark clinical trials proved that LDCT screening saves lives (NLST trial – 20% mortality reduction; NELSON trial – 24% mortality reduction)?
NLST and NELSON.

407. What are the current USPSTF (US Preventive Services Task Force) guidelines for lung cancer screening?
Annual LDCT for adults aged 50–80 with ≥20 pack-years who currently smoke or quit within 15 years.

408. Who qualifies for annual LDCT lung cancer screening under USPSTF guidelines?
Age 50–80, ≥20 pack-years, current smoker or quit within 15 years.

409. Age range: 50 to 80 years old.
Correct.

410. Smoking history: 20 or more pack-years of smoking.
Correct.

411. Smoking status: Current smoker or former smoker who quit within the past 15 years.
Correct.

412. When can annual lung cancer screening be safely stopped?
At age 81, after 15 years of quitting, or when life expectancy is limited.

413. When a person turns 81, or has been quit for 15+ years, or develops a health problem that limits life expectancy or ability to undergo curative surgery.
Correct.

414. What percentage of eligible high-risk Americans actually receive annual LDCT screening (<10%)?
Less than 10%.

415. Why is lung cancer screening uptake so low compared to mammograms or colonoscopies (lack of provider/patient awareness, stigma, fear)?
Lack of awareness, stigma, and fear.

416. Is annual LDCT screening covered by Medicare and private insurance without co-pay for qualifying individuals?
Yes, generally covered.

417. What is a “shared decision-making” (SDM) visit before lung cancer screening?
A discussion of benefits, harms, and preferences.

418. What topics are discussed during a shared decision-making consultation (benefits, potential harms, false positives, smoking cessation support)?
Benefits, harms, false positives, and cessation support.

419. What are the main benefits of annual LDCT screening (catching NSCLC at Stage 1 when cure rate is >80–90%)?
Early detection and improved survival.

420. What are the potential harms or risks of LDCT screening?
False positives, overdiagnosis, radiation, and anxiety.

421. Risk 1: High false-positive rate (detecting benign nodules that require follow-up).
Correct.

422. Risk 2: Overdiagnosis (finding slow-growing indolent tumors that might not have caused harm during lifetime).
Correct.

423. Risk 3: Low radiation exposure from annual scans (minimal risk compared to screening benefit).
Correct.

424. Risk 4: Patient anxiety (“scanxiety”) waiting for results.
Correct.

425. What is the Lung-RADS (Lung CT Screening Reporting and Data System) classification system?
A standardized system for reporting screening CT findings.

426. What does Lung-RADS Category 1 mean (Negative – <1% chance of malignancy; resume annual screening)?
Negative; continue annual screening.

427. What does Lung-RADS Category 2 mean (Benign appearance – <1% chance of malignancy; resume annual screening)?
Benign; continue annual screening.

428. What does Lung-RADS Category 3 mean (Probably benign – 1–2% chance of malignancy; recommended 6-month follow-up LDCT)?
Probably benign; 6-month follow-up.

429. What does Lung-RADS Category 4A mean (Suspicious – 5–15% chance of malignancy; recommended 3-month LDCT or PET-CT)?
Suspicious; 3-month follow-up or PET-CT.

430. What does Lung-RADS Category 4B / 4X mean (Very suspicious – >15% chance of malignancy; recommended diagnostic workup / tissue biopsy)?
Very suspicious; diagnostic workup.

431. What is an incidental pulmonary nodule?
A nodule found on imaging for unrelated reasons.

432. How are incidental nodules found (on CT scans performed for unrelated reasons e.g., ER trauma, heart workup, abdominal scans)?
Incidentally on CT scans.

433. What guidelines manage incidental lung nodules (Fleischner Society Guidelines)?
Fleischner Society Guidelines.

434. How do Fleischner Society Guidelines determine nodule follow-up based on nodule size, solid vs subsolid features, and patient risk level?
They stratify follow-up by size, density, and risk.

435. What nodule size threshold usually requires no follow-up in low-risk individuals (<6 mm solid nodule)?
<6 mm solid nodules in low-risk individuals.

436. What nodule features increase suspicion of malignancy?
Size >8–10 mm, spiculated margins, upper lobe location, solid/part-solid, and growth.

437. Size >8–10 mm, spiculated/jagged edges, upper lobe location, solid or part-solid component, growth over time.
Correct.

438. What nodule features suggest a benign process?
Size <6 mm, smooth borders, calcification, and stability.

439. Size <6 mm, smooth/round borders, central or “popcorn” calcification, stability over 2+ years.
Correct.

440. What is doubling time in pulmonary nodules?
Time for a nodule to double in volume.

441. What is the average volume doubling time for malignant NSCLC nodules (typically 30 to 400 days)?
30–400 days.

442. What does a doubling time of <30 days suggest (acute infection or inflammation)?
Infection or inflammation.

443. What does a doubling time of >400–500 days suggest (benign lesion or slow indolent AIS)?
Benign or indolent lesion.

444. How is volumetric CT analysis used to measure 3D nodule growth accurately?
It measures volume in three dimensions.

445. What is Artificial Intelligence (AI) and deep learning in lung nodule detection?
AI assists radiologists in detecting and characterizing nodules.

446. How does AI software assist radiologists in detecting tiny nodules and predicting malignancy probability scores?
It flags suspicious nodules and provides risk scores.

447. What liquid biopsy / blood-based screening tests are in development for lung cancer?
ctDNA and multi-cancer early detection tests.

448. What are circulating tumor DNA (ctDNA) blood screening assays (e.g., multi-cancer early detection / MCED tests)?
Blood tests that detect tumor DNA.

449. Can blood tests currently replace LDCT scans for lung cancer screening (no, LDCT remains the gold standard; blood tests are investigational)?
No.

450. What airway biomarker tests (e.g., nasal swab gene expression, sputum cytology) assist in evaluating indeterminate nodules?
Investigational adjuncts.

451. What is a PET-CT scan, and how is it used to evaluate indeterminate lung nodules (>8 mm)?
It assesses metabolic activity.

452. How does FDG tracer uptake (SUV max) evaluate metabolic activity in a nodule?
Higher SUV max suggests malignancy.

453. What causes false-positive high SUV uptake on PET scans (active infections like fungal disease, TB, sarcoidosis, inflammation)?
Infection and inflammation.

454. What causes false-negative low SUV uptake on PET scans (slow-growing adenocarcinomas in situ, carcinoid tumors, lesions <8–10 mm)?
Slow-growing tumors and small lesions.

455. What non-surgical biopsy methods evaluate suspicious lung nodules?
Bronchoscopy, CT-guided needle biopsy, and navigation bronchoscopy.

456. What is Robotic-Assisted Bronchoscopy (e.g., Ion, Monarch systems)?
Robotic bronchoscopy for peripheral nodule biopsy.

457. How does robotic bronchoscopy navigate deep into outer peripheral lung tissue to biopsy tiny nodules accurately?
Using robotic navigation.

458. What is Electromagnetic Navigation Bronchoscopy (ENB)?
Navigation bronchoscopy using electromagnetic tracking.

459. What is Radial Endobronchial Ultrasound (r-EBUS) for peripheral nodule visualization?
Radial ultrasound to locate peripheral nodules.

460. What is CT-guided Transthoracic Needle Aspiration (TTNA) / core needle biopsy?
Needle biopsy through the chest wall guided by CT.

461. What is the main complication risk of CT-guided needle lung biopsy (pneumothorax / collapsed lung – ~15–25% risk, ~5% requiring chest tube)?
Pneumothorax.

462. What is a pneumothorax, and how is it treated if a lung biopsy causes an air leak?
Air in pleural space; may need chest tube.

463. What is Liquid Biopsy for indeterminate nodules (plasma ctDNA testing)?
Blood test for tumor DNA.

464. How do multidisciplinary lung nodule clinics evaluate complex or borderline nodules?
Team review.

465. Who staffs a multidisciplinary lung nodule clinic (pulmonologists, thoracic surgeons, radiologists, interventional radiologists)?
These specialists.

466. How does early detection via screening shift NSCLC stage distribution from Stage 4 to Stage 1?
Screening shifts diagnosis to earlier stages.

467. What is the 5-year survival rate for Stage 1A NSCLC detected by LDCT (>80–90%)?

80–90%.

468. What is the 5-year survival rate for Stage 4 NSCLC detected after symptoms appear (~9%)?
~9%.

469. How can expanded screening criteria save more lives among high-risk never-smokers or light smokers?
By including more high-risk individuals.

470. Why are international guidelines evaluating adding family history or genetic risk scores to screening eligibility?
To identify more high-risk individuals.

471. What should a patient do if their screening LDCT shows a “spot on the lung”?
Consult a pulmonologist for follow-up.

472. Don’t panic: >90% of small spots are benign scars/granulomas; consult a pulmonologist for a structured management plan.
Correct.

473. What is a non-calcified lung nodule?
A nodule without calcification, which may be malignant.

474. Why does calcification in a nodule usually indicate a past healed infection rather than cancer?
Calcification is typical of healed granulomas.

475. What is a “popcorn calcification” pattern characteristic of (benign pulmonary hamartoma)?
Hamartoma.

476. What is a “bull’s-eye” or concentric calcification pattern characteristic of (granulomatous infection like histoplasmosis)?
Granulomatous infection.

477. What happens if a lung nodule remains stable in size on CT for 2 consecutive years?
Suggests benign process.

478. Two-year size stability on high-resolution CT strongly suggests a benign process.
Correct.

479. What follow-up schedule is required for ground-glass opacities (GGOs)?
Annual CT for 3–5 years.

480. GGOs grow very slowly and often require annual CT monitoring for 3 to 5 years.
Correct.

481. What causes a ground-glass nodule to develop a solid core (indicates progression toward invasive adenocarcinoma)?
Progression to invasive adenocarcinoma.

482. When is surgical excisional biopsy (wedge resection) recommended for a growing nodule?
When nodule grows or becomes suspicious.

483. What questions should you ask your doctor about a lung nodule CT result?
Ask about size, density, Lung-RADS score, and follow-up.

484. “What is the exact size, location, and density (solid vs ground-glass) of the nodule?”
Correct.

485. “What is my Lung-RADS score?”
Correct.

486. “Do I need a repeat CT in 3–6 months, a PET scan, or a biopsy?”
Correct.

487. How do patients manage anxiety while waiting for follow-up repeat CT scans (“scanxiety”)?
Counseling and support.

488. What digital health tools track nodule dimensions across serial CT scans?
Radiology software and patient portals.

489. How do electronic health record (EHR) registries ensure high-risk nodules aren’t lost to follow-up?
Tracking systems.

490. What is the role of mobile CT screening units in reaching rural or underserved communities?
They bring screening to underserved areas.

491. How does smoking cessation counseling integrated into screening programs double quit success rates?
Combining screening with cessation support.

492. What insurance codes (CPT codes 71271) cover low-dose screening CT scans?
CPT 71271.

493. What resources assist patients who face insurance denial for LDCT screening?
Patient navigators and appeals.

494. What is the message of empowerment behind screening?
Screening is quick, painless, and detects cancer early.

495. LDCT screening takes 10 seconds, is pain-free, uses no needles, and catches lung cancer when it is most curable.
Correct.

496. Where can individuals find accredited ACR (American College of Radiology) lung cancer screening centers near them?
ACR website.

497. How do patient advocacy groups work to expand screening guidelines to cover broader populations?
Through advocacy and education.

498. What summary takeaway summarizes lung cancer screening?
If eligible, annual LDCT screening can detect lung cancer early.

499. If you are aged 50–80 with a 20+ pack-year smoking history, ask your doctor for an annual Low-Dose CT scan today.
Correct.

500. Early detection transforms NSCLC from a fatal disease into a treatable, curable condition.
Correct.

501. How is NSCLC diagnosed?
Imaging, biopsy, pathology, and staging.

502. Can NSCLC be definitively diagnosed by an X-ray or CT scan alone?
No; tissue biopsy is required.

503. Why is a tissue biopsy MANDATORY to confirm a diagnosis of NSCLC?
It provides histologic confirmation and molecular profiling.

504. What is the diagnostic workup sequence for suspected NSCLC?
Clinical evaluation, CT, biopsy, pathology, biomarker testing, and staging scans.

505. Step 1: Clinical evaluation + Diagnostic Contrast CT of Chest/Upper Abdomen.
Correct.

506. Step 2: Tissue Biopsy (Bronchoscopy, CT-guided needle, or lymph node biopsy).
Correct.

507. Step 3: Pathology + Immunohistochemistry + Biomarker/Genomic Testing.
Correct.

508. Step 4: Systemic Staging Scans (PET-CT + Brain MRI).
Correct.

509. What is a Diagnostic Chest CT scan with IV contrast?
A contrast-enhanced CT for detailed imaging.

510. How does a diagnostic CT differ from a low-dose screening CT (uses contrast dye, higher resolution, evaluates mediastinal vessels/nodes)?
It uses contrast and higher resolution.

511. What is a PET-CT scan (Positron Emission Tomography)?
Metabolic imaging combined with CT.

512. How does FDG (fluorodeoxyglucose) radioactive glucose tracer highlight cancer cells on a PET scan?
Cancer cells take up more glucose.

513. Why is a PET-CT scan performed for all newly diagnosed NSCLC patients (to detect hidden regional lymph node spread or distant metastases)?
To detect occult metastases.

514. What is a Brain MRI with IV contrast?
MRI of the brain with contrast.

515. Why is Brain MRI mandatory for staging NSCLC (except Stage 1A NSCLC without symptoms)?
To detect brain metastases.

516. Why is Brain MRI preferred over Brain CT (much higher sensitivity for detecting microscopic brain metastases)?
Higher sensitivity.

517. What biopsy procedures are used to collect NSCLC tissue samples?
Bronchoscopy, CT-guided needle biopsy, EBUS, mediastinoscopy, VATS.

518. What is a Flexible Fiberoptic Bronchoscopy?
A thin camera scope for airway visualization and biopsy.

519. How is a bronchoscopy performed (thin flexible camera scope passed through nose/mouth into bronchial airways under conscious sedation)?
Under conscious sedation.

520. What is Endobronchial Ultrasound (EBUS / EBUS-TBNA)?
Ultrasound-guided needle biopsy of mediastinal nodes.

521. Why is EBUS-TBNA (Transbronchial Needle Aspiration) the gold standard for sampling mediastinal and hilar lymph nodes?
It is minimally invasive and highly accurate.

522. How does EBUS allow real-time ultrasound visualization of lymph nodes outside bronchial walls?
Real-time imaging.

523. What is CT-guided Transthoracic Needle Biopsy (Fine Needle Aspiration / Core Needle Biopsy)?
Needle biopsy through the chest wall.

524. How is a CT-guided needle biopsy performed on a peripheral lung lesion (radiologist inserts needle through chest wall guided by real-time CT)?
Under CT guidance.

525. What is Thoracentesis?
Needle drainage of pleural fluid.

526. How is thoracentesis performed (needle inserted into pleural space to drain fluid and analyze for malignant cells)?
Needle drainage.

527. What is Pleural Biopsy?
Biopsy of the pleura.

528. What is Video-Assisted Thoracoscopic Surgery (VATS) or Medical Thoracoscopy?
Minimally invasive surgery to inspect the pleura.

529. When is VATS used diagnostically (to inspect pleura, collect direct tissue biopsies, or manage recurrent pleural effusions)?
For pleural biopsy, staging, or effusion management.

530. What is Mediastinoscopy?
Surgical biopsy of mediastinal lymph nodes.

531. What is a Supraclavicular Lymph Node Biopsy?
Biopsy of supraclavicular nodes.

532. What is the AJCC / IASLC 8th Edition TNM Staging System for NSCLC?
TNM staging by tumor, node, and metastasis.

533. What does ‘T’ stand for (Tumor size and local invasive extent: T1a, T1b, T1c, T2a, T2b, T3, T4)?
T describes primary tumor size and invasion.

534. What is T1a (≤1 cm), T1b (>1 to ≤2 cm), T1c (>2 to ≤3 cm)?
Small tumors.

535. What is T2a (>3 to ≤4 cm), T2b (>4 to ≤5 cm)?
Larger tumors.

536. What is T3 (>5 to ≤7 cm or separate tumor nodule in same lobe or chest wall invasion)?
T3.

537. What is T4 (>7 cm or invasion of heart, great vessels, trachea, esophagus, spine, or separate nodule in different ipsilateral lobe)?
T4.

538. What does ‘N’ stand for (Regional lymph node involvement: N0, N1, N2, N3)?
N describes nodal involvement.

539. What is N0 (no regional lymph node spread)?
No nodes.

540. What is N1 (spread to ipsilateral/same-side hilar or peribronchial nodes)?
N1.

541. What is N2 (spread to ipsilateral mediastinal or subcarinal nodes)?
N2.

542. What is N3 (spread to contralateral/opposite mediastinal/hilar nodes or supraclavicular nodes)?
N3.

543. What does ‘M’ stand for (Distant Metastasis: M0, M1a, M1b, M1c)?
M describes metastasis.

544. What is M1a (malignant pleural/pericardial effusion, pleural nodules, or contralateral lung nodule)?
Intrathoracic metastasis.

545. What is M1b (single distant metastatic lesion in one organ e.g. single brain or bone lesion – oligometastatic)?
Single extrathoracic metastasis.

546. What is M1c (multiple distant metastatic lesions in one or multiple organs)?
Multiple metastases.

547. What is Stage 0 NSCLC (Tis – Carcinoma in situ)?
Carcinoma in situ.

548. What is Stage 1A1, 1A2, 1A3 NSCLC (small invasive tumor ≤3 cm, N0, M0)?
Stage I small tumors.

549. What is Stage 1B NSCLC (tumor >3 cm to ≤4 cm, N0, M0)?
Stage IB.

550. What is Stage 2A and 2B NSCLC (larger tumor or N1 lymph node involvement, M0)?
Stage II.

551. What is Stage 3A NSCLC (locally advanced, often N2 node involvement or chest wall invasion)?
Stage IIIA.

552. What is Stage 3B and 3C NSCLC (locally advanced, extensive N2/N3 node involvement, unresectable)?
Stage IIIB/IIIC.

553. What is Stage 4A NSCLC (M1a pleural/pericardial spread or single distant metastasis M1b)?
Stage IVA.

554. What is Stage 4B NSCLC (widespread distant metastases M1c)?
Stage IVB.

555. What basic blood work is ordered during an NSCLC diagnostic workup (CBC, CMP, LFTs, Kidney function, LDH, Calcium)?
CBC, CMP, LFTs, renal function, LDH, and calcium.

556. Are serum tumor markers (CEA, CYFRA 21-1, NSE) useful for routine NSCLC diagnosis (not recommended for primary diagnosis; used occasionally for monitoring)?
Not recommended for diagnosis.

557. What is Pulmonary Function Testing (PFT) / Spirometry?
Lung function tests.

558. Why is PFT testing mandatory before considering lung surgery (evaluates FEV1 and DLCO to ensure remaining lung tissue can support breathing)?
To ensure adequate lung function.

559. What is Quantitative Ventilation/Perfusion (V/Q) Scan (used to calculate post-operative lung function if PFTs are borderline)?
V/Q scan.

560. What is Cardiac Clearance (Echocardiogram / Stress Test) before lung surgery or aggressive chemo?
Cardiac evaluation.

561. What is clinical stage (cTNM) vs pathological stage (pTNM)?
Clinical stage is before surgery; pathological stage is after surgery.

562. How is post-neoadjuvant stage reported (ypTNM)?
With a “yp” prefix.

563. What is an Indeterminate Stage classification, and how do multidisciplinary tumor boards resolve staging ambiguities?
Tumor boards review ambiguous findings.

564. How long does a complete diagnostic and staging workup take (typically 2 to 4 weeks)?
2–4 weeks.

565. What is the risk of biopsy complications (bleeding, infection, pneumothorax)?
Bleeding, infection, and pneumothorax.

566. How should a patient care for a needle biopsy or bronchoscopy site at home?
Keep clean, monitor for bleeding or fever.

567. What signs of post-biopsy complications require immediate emergency medical care (coughing up large amounts of blood, severe sudden dyspnea, high fever)?
Seek emergency care for severe bleeding, breathlessness, or fever.

568. What questions should you ask your doctor about your diagnostic pathology report?
Ask about histology, biomarkers, stage, and treatment plan.

569. “What is the exact histologic type of my lung cancer?”
Correct.

570. “Has biomarker / Next-Generation Sequencing (NGS) testing been ordered?”
Correct.

571. “What is my exact TNM numerical stage?”
Correct.

572. “Are my brain MRI and PET-CT scans complete?”
Correct.

573. Why is getting a second opinion at a specialized academic Comprehensive Cancer Center recommended after diagnosis?
Second opinions can confirm diagnosis and treatment plan.

574. How do second opinions change treatment plans in up to 20–30% of NSCLC cases?
They can lead to changes in staging or treatment.

575. What documents must be transferred when seeking a second opinion (pathology slides, CT/PET/MRI discs, NGS reports)?
Pathology slides, imaging discs, and molecular reports.

576. What role does a Nurse Navigator play during the diagnostic workup?
They coordinate appointments and provide support.

577. How do financial navigators assist with insurance pre-authorizations for PET scans, Brain MRIs, and NGS testing?
They help obtain insurance approvals.

578. What diagnostic coding (ICD-10 C34.9) identifies NSCLC?
C34.9.

579. What is a multidisciplinary tumor board review?
A team of specialists reviews the case to agree on a plan.

580. How does a tumor board bring together thoracic surgeons, medical oncologists, radiation oncologists, radiologists, and pathologists to agree on a unified treatment plan?
They collaborate to create a unified plan.

581. Is surgery a curative treatment for NSCLC?
Yes, for early-stage NSCLC.

582. Which NSCLC patients are candidates for surgery (primarily Stage 1, Stage 2, and select Stage 3A NSCLC)?
Stage I–II and select IIIA NSCLC.

583. Why is surgery rarely performed for Stage 4 metastatic NSCLC (except for select oligometastatic cases)?
Surgery does not improve survival in widespread metastatic disease.

584. What is the primary goal of NSCLC surgery (complete surgical resection with clear margins / R0 resection)?
Complete resection with clear margins.

585. What are the main types of lung cancer surgical operations?
Lobectomy, segmentectomy, wedge resection, pneumonectomy.

586. What is a Lobectomy?
Removal of an entire lung lobe.

587. Why is Lobectomy (removing the entire affected lung lobe) historical gold standard operation for early-stage NSCLC?
It provides the best oncologic control.

588. What is a Sublobar Resection?
Removal of less than a lobe.

589. What is a Segmentectomy (anatomical removal of a specific lung segment with its artery, vein, and airway)?
Anatomical removal of a lung segment.

590. What is a Wedge Resection (non-anatomical removal of a pie-shaped wedge of lung tissue containing the tumor)?
Non-anatomical removal of a wedge of tissue.

591. When is Segmentectomy preferred over Lobectomy (proved equal to lobectomy for small peripheral tumors ≤2 cm in CALGB 140503 and JCOG0802 trials)?
For small peripheral tumors ≤2 cm.

592. When is Wedge Resection used (for patients with poor lung function who cannot tolerate segmentectomy or lobectomy)?
For patients with limited lung function.

593. What is a Pneumonectomy (removal of the entire lung)?
Removal of the entire lung.

594. When is Pneumonectomy required (for large central tumors involving the main stem bronchus or main pulmonary artery)?
For central tumors not amenable to lesser resection.

595. Why is Pneumonectomy avoided whenever possible (higher surgical risk and permanent impact on breathing capacity)?
It carries higher risk.

596. What is a Sleeve Resection / Bronchoplastic Resection?
Resection of a bronchial segment with reattachment.

597. How does a sleeve resection allow surgeons to save healthy lung tissue while removing a central airway tumor (resecting a ring of bronchus and reattaching the remaining lung)?
It preserves distal lung tissue.

598. What is Mediastinal Lymph Node Dissection (MLND) / Systematic Lymph Node Sampling?
Removal and mapping of mediastinal lymph nodes.

599. Why is removing and mapping regional lymph nodes mandatory during all NSCLC surgeries (to ensure accurate staging and remove microscopic spread)?
For accurate staging and local control.

600. What surgical approaches are used to perform lung surgery?
Open thoracotomy, VATS, and robotic-assisted surgery.

601. What is Open Thoracotomy (traditional surgery using a larger chest incision between ribs)?
Open chest surgery.

602. What is Video-Assisted Thoracoscopic Surgery (VATS)?
Minimally invasive surgery using small incisions and a camera.

603. How is VATS performed (minimally invasive surgery using 1 to 3 small incisions, a camera scope, and specialized instruments)?
Through small incisions with camera guidance.

604. What is Robotic-Assisted Thoracic Surgery (RATS) (e.g., da Vinci robotic system)?
Robotic surgery using articulated instruments.

605. What are the benefits of VATS and RATS over open thoracotomy (less pain, shorter hospital stay, faster recovery, fewer wound complications)?
Less pain, shorter stay, faster recovery.

606. How long does a Lobectomy surgery take (typically 2 to 4 hours)?
2–4 hours.

607. How long is the hospital stay after minimally invasive lung surgery (VATS/RATS: 2 to 4 days)?
2–4 days.

608. How long is the hospital stay after an open thoracotomy (4 to 7 days)?
4–7 days.

609. What surgical chest tube is placed during lung surgery?
A chest tube drains air and fluid.

610. What is the purpose of a chest tube (drains residual air, fluid, or blood from the pleural space to allow the lung to fully re-expand)?
To re-expand the lung and prevent fluid accumulation.

611. How long does a chest tube stay in place after lung surgery (typically 1 to 4 days, until air leak stops and fluid drainage drops)?
1–4 days.

612. What is an air leak after lung surgery, and how is it managed?
Air leak from lung tissue; managed with chest tube and observation.

613. What is a Heimlich valve or digital chest drain system (e.g., Thopaz) for portable air leak management?
Devices for outpatient air leak management.

614. What pain management protocols are used for thoracic surgery?
Multimodal analgesia including nerve blocks and opioids.

615. What is Enhanced Recovery After Surgery (ERAS) protocol for thoracic operations?
A standardized perioperative care pathway.

616. What nerve blocks are used for lung surgery pain control (Epidural, Paravertebral block, Intercostal nerve block, PECS/Serratus blocks)?
Epidural, paravertebral, intercostal, and PECS blocks.

617. Why is effective pain control critical after lung surgery (enables deep breathing, coughing, and early walking to prevent pneumonia)?
To prevent complications and promote recovery.

618. What is Incentive Spirometry, and how does it expand lung volume post-surgery?
A device to encourage deep breathing.

619. How soon after lung surgery should a patient start walking (within hours of waking up / Day 1)?
Within hours to day 1.

620. What are common surgical complications of thoracic surgery?
Air leak, atrial fibrillation, pneumonia, bleeding, DVT/PE, infection.

621. Complication 1: Persistent air leak (>5 days).
Correct.

622. Complication 2: Atrial Fibrillation (AFib / irregular heart rhythm – ~15–20% risk).
Correct.

623. Complication 3: Post-operative Pneumonia or Atelectasis (lung collapse).
Correct.

624. Complication 4: Bleeding or Hemothorax.
Correct.

625. Complication 5: Deep Vein Thrombosis (DVT) / Pulmonary Embolism (PE).
Correct.

626. Complication 6: Wound infection or empyema (infected pleural fluid).
Correct.

627. Complication 7: Bronchopleural Fistula (BPF – rare connection between airway and pleural space).
Correct.

628. What is Post-Thoracotomy Pain Syndrome (PTPS) or chronic incisional pain?
Chronic pain after thoracotomy.

629. What causes PTPS (intercostal nerve irritation or entrapment during surgery)?
Nerve irritation or entrapment.

630. How is chronic post-op pain managed (neuropathic pain drugs like Gabapentin/Pregabalin, physical therapy, nerve blocks)?
Neuropathic agents, physical therapy, nerve blocks.

631. What is Neoadjuvant Therapy (treatment given BEFORE surgery)?
Treatment before surgery.

632. What is Neoadjuvant Chemo-Immunotherapy for resectable Stage 2 to 3B NSCLC?
Combination of chemo and immunotherapy before surgery.

633. What did landmark trials (CheckMate 816, KEYNOTE-671, AEGEAN, CheckMate 77T) prove about pre-op chemo + immunotherapy?
They improved pathologic complete response and event-free survival.

634. Combining platinum chemo + PD-1/PD-L1 immunotherapy before surgery dramatically increases Pathologic Complete Response (pCR) rates and event-free survival.
Correct.

635. What is Pathologic Complete Response (pCR) in lung surgery (no active cancer cells found in excised lung tissue or lymph nodes after pre-op treatment)?
No viable tumor cells at surgery.

636. What is Major Pathologic Response (MPR) (≤10% viable tumor cells remaining)?
≤10% viable tumor cells.

637. What is Adjuvant Therapy (treatment given AFTER surgery)?
Treatment after surgery.

638. What is Adjuvant Targeted Therapy (Osimertinib / Tagrisso for EGFR-mutated NSCLC – ADAURA trial)?
Osimertinib after surgery for EGFR-mutant NSCLC.

639. What did the ADAURA trial prove (3 years of daily Osimertinib after surgery reduces recurrence risk by >80% in EGFR+ Stage 1B–3A NSCLC)?
It significantly reduced recurrence risk.

640. What is Adjuvant Targeted Therapy (Alectinib / Alecensaro for ALK-positive NSCLC – ALINA trial)?
Alectinib after surgery for ALK-positive NSCLC.

641. What is Adjuvant Targeted Therapy (Selpercatinib for RET fusion-positive NSCLC – LIBRETTO-432 trial)?
Selpercatinib after surgery for RET fusion-positive NSCLC.

642. What is Adjuvant Immunotherapy (Atezolizumab or Pembrolizumab after adjuvant chemo for PD-L1+ NSCLC)?
Immunotherapy after surgery.

643. What is Adjuvant Platinum-Based Chemotherapy (Cisplatin + Vinorelbine or Pemetrexed)?
Platinum-based chemotherapy after surgery.

644. How much does adjuvant chemotherapy improve 5-year overall survival in Stage 2–3 NSCLC (~4–5% absolute survival gain)?
About 4–5%.

645. When is surgery considered for Pancoast tumors (requires pre-op chemo/radiation followed by complex chest wall/spine resection)?
After neoadjuvant therapy.

646. What is an unexpected N2 lymph node finding during surgery (discovering positive mediastinal nodes during operation)?
Positive N2 nodes found at surgery.

647. How is unexpected N2 disease managed post-operatively (adjuvant chemo + radiation + targeted/immunotherapy)?
Adjuvant chemo, radiation, and targeted/immunotherapy.

648. Can a patient live normally with only one lung after a pneumonectomy?
Yes, with adaptation.

649. How does the remaining lung compensate over time (gradual expansion and physiological adaptation)?
It expands and compensates.

650. What physical restrictions apply after lung surgery (no heavy lifting >10–15 lbs for 4–6 weeks, no flying for 4–6 weeks)?
Avoid heavy lifting and flying.

651. When can a patient drive a car after lung surgery (when off narcotic pain medications and moving arms freely)?
When off narcotics and mobile.

652. When can a patient return to work after lung surgery (typically 4 to 8 weeks depending on physical job demands)?
4–8 weeks.

653. What is Thoracic Physical Therapy and Pulmonary Rehabilitation post-surgery?
Rehab to improve breathing and function.

654. How does pulmonary rehab improve exercise capacity, breathing efficiency, and quality of life?
It improves exercise tolerance.

655. What chest wall numbness occurs after lung surgery (numbness below incision due to intercostal nerve stretching; resolves gradually)?
Numbness below the incision.

656. How do surgeons manage positive surgical margins (R1 / R2 resection) if cancer cells reach the cut edge?
Re-excision or post-operative radiation.

657. Re-excision if feasible, or post-operative radiation therapy + systemic treatment.
Correct.

658. What non-surgical local ablation options exist for patients unfit for surgery?
SBRT, radiofrequency ablation, cryoablation.

659. What is Stereotactic Body Radiation Therapy (SBRT / SABR) as a surgical alternative?
High-dose precision radiation.

660. What is Thermal Ablation (Radiofrequency Ablation / RFA or Cryoablation) for lung tumors?
Heat or cold ablation.

661. What questions should you ask your thoracic surgeon before lung surgery?
Ask about approach, extent, margins, and recovery.

662. “Am I a candidate for a minimally invasive approach (VATS or Robotic)?”
Correct.

663. “Are we planning a Lobectomy or Segmentectomy?”
Correct.

664. “Will you perform a systematic mediastinal lymph node dissection?”
Correct.

665. “Are neoadjuvant chemo-immunotherapy or adjuvant targeted therapies indicated for my stage?”
Correct.

666. “What is your personal and institution’s surgical volume for this operation?”
Correct.

667. Why is choosing a dedicated board-certified Thoracic Surgeon (rather than a general surgeon) recommended?
Better outcomes.

668. What items should a patient pack in their hospital bag for lung surgery recovery?
Comfortable clothes, toiletries, phone charger.

669. How should a patient prepare their home for post-op recovery (front-clasp shirts, extra pillows, incentive spirometer)?
Set up a comfortable recovery area.

670. What non-profit resources offer lodging support near surgical centers (e.g., ACS Hope Lodge)?
ACS Hope Lodge.

671. How does quitting smoking immediately before surgery reduce post-op lung complications by 50%?
Smoking cessation improves healing.

672. What pre-habilitation (pre-op exercise and breathing practice) optimizes post-op surgical recovery?
Pre-op exercise and breathing exercises.

673. How do multidisciplinary surgical tumor boards coordinate perioperative care?
Through team meetings.

674. What digital health apps track post-op spirometry volumes and wound healing photos?
Some rehab apps.

675. What physical signs of wound infection require an immediate call to the surgical team (pus, worsening redness, fever, chest wall swelling)?
Report pus, redness, fever, or swelling.

676. Where can patients view surgical videos and patient instruction handbooks from the STS (Society of Thoracic Surgeons)?
STS website.

677. What summary message reassures surgical candidates?
Modern surgery offers high cure rates with good recovery.

678. Modern minimally invasive lung surgery (VATS/Robotic) combined with new perioperative therapies offers the highest cure rates in history.
Correct.

679. Follow breathing exercises daily, walk as much as tolerated, and take prescribed pain medication to support full recovery.
Correct.

680. Celebrate completing surgical resection as a major milestone on your path toward cure!
Correct.

681. What is Radiation Therapy for NSCLC?
High-energy radiation to kill cancer cells.

682. How does radiation therapy work (uses high-energy X-rays or protons to damage cancer cell DNA and prevent growth)?
It damages DNA.

683. In what clinical scenarios is radiation therapy used for NSCLC?
Definitive, adjuvant, neoadjuvant, and palliative.

684. Scenario 1: Definitive curative treatment for early-stage NSCLC in patients unfit for surgery (SBRT/SABR).
Correct.

685. Scenario 2: Definitive concurrent chemo-radiation for unresectable Stage 3 NSCLC.
Correct.

686. Scenario 3: Neoadjuvant or Adjuvant radiation around surgery.
Correct.

687. Scenario 4: Palliative radiation to relieve symptoms (pain, bleeding, airway blockage, brain/bone metastases).
Correct.

688. What are the main radiation delivery techniques used for NSCLC?
SBRT, IMRT, VMAT, 3D-CRT, proton therapy.

689. What is Stereotactic Body Radiation Therapy (SBRT) / Stereotactic Ablative Radiotherapy (SABR)?
Ultra-precise high-dose radiation.

690. How does SBRT deliver ultra-precise, high-dose radiation in 1 to 5 treatment sessions?
Using image guidance.

691. What is the local control rate of SBRT for early Stage 1 NSCLC (>90% local tumor control)?

90%.

692. What is Intensity-Modulated Radiation Therapy (IMRT)?
Shaped radiation beams.

693. What is Volumetric Modulated Arc Therapy (VMAT)?
Advanced IMRT using rotating arcs.

694. What is 3D-Conformal Radiation Therapy (3D-CRT)?
Three-dimensional shaping.

695. What is Image-Guided Radiation Therapy (IGRT) using daily Cone-Beam CT alignment?
Daily imaging verification.

696. What is Proton Beam Therapy, and when is it used for NSCLC (to spare surrounding normal heart, esophagus, and healthy lung tissue)?
Precise proton radiation.

697. What is Motion Management / 4D-CT Simulation during lung radiation?
Imaging that accounts for breathing motion.

698. How do radiation oncologists track lung tumor movement during normal breathing (gating, breath-hold techniques, CyberKnife fiducial tracking)?
Gating and tracking.

699. What is Deep Inspiration Breath Hold (DIBH) or Abdominal Compression?
Techniques to reduce motion.

700. What total radiation dose is delivered during standard definitive radiation (typically 60 to 66 Gray / Gy in 30 to 33 daily fractions over 6 weeks)?
60–66 Gy.

701. What total dose is delivered during SBRT (typically 48 to 60 Gy in 3 to 5 fractions over 1 to 2 weeks)?
48–60 Gy.

702. What is Concurrent Chemo-Radiation (chemotherapy and radiation delivered at the same time)?
Chemo and radiation together.

703. Why is concurrent chemo-radiation superior to sequential chemo followed by radiation (higher tumor control and overall survival)?
It improves local control and survival.

704. What chemotherapy regimen is combined with radiation for Stage 3 NSCLC (Carboplatin + Paclitaxel or Cisplatin + Pemetrexed)?
Platinum-based doublet.

705. What is Consolidation Immunotherapy after chemo-radiation for Stage 3 NSCLC (Durvalumab / Imfinzi – PACIFIC trial)?
Durvalumab after chemoradiation.

706. What did the landmark PACIFIC trial prove about Durvalumab?
It improved progression-free and overall survival.

707. Giving 1 year of Durvalumab after chemo-radiation for unresectable Stage 3 NSCLC dramatically extends overall survival (5-year survival ~43% vs 33% placebo).
Correct.

708. What is Stereotactic Radiosurgery (SRS) / Gamma Knife / CyberKnife for NSCLC Brain Metastases?
Precise single-fraction radiation.

709. How does SRS target isolated brain metastases with millimeter precision in a single session without radiating the whole brain?
Stereotactic localization.

710. Why is SRS preferred over Whole-Brain Radiation Therapy (WBRT) for oligometastatic brain disease (preserves memory, cognition, and quality of life)?
It spares normal brain tissue.

711. When is Whole-Brain Radiation Therapy (WBRT) still used (for widespread, multiple >10+ brain metastases or leptomeningeal disease)?
For numerous metastases.

712. What are the acute (short-term) side effects of lung radiation therapy?
Fatigue, esophagitis, skin redness, and cough.

713. Side Effect 1: Fatigue (peaks toward end of treatment; resolves in weeks).
Correct.

714. Side Effect 2: Radiation Esophagitis (painful or difficult swallowing / heartburn when radiation field is near chest center).
Correct.

715. How is radiation esophagitis managed (magic mouthwash, liquid antacids, soft bland diet, pain meds)?
Symptomatic relief.

716. Side Effect 3: Skin redness or dry peeling over treatment area (radiation dermatitis).
Correct.

717. Side Effect 4: Mild dry cough or temporary increase in breathlessness.
Correct.

718. What are the chronic (long-term or delayed) side effects of lung radiation?
Pneumonitis, fibrosis, cardiac toxicity, esophageal stricture, rib fracture.

719. What is Radiation Pneumonitis (lung inflammation occurring 1 to 6 months after radiation)?
Lung inflammation.

720. What are the symptoms of Radiation Pneumonitis (new/worsening dry cough, shortness of breath, low-grade fever)?
Cough, dyspnea, and fever.

721. How is Radiation Pneumonitis treated (oral corticosteroid taper e.g. Prednisone for 4 to 8 weeks)?
Corticosteroids.

722. What is Radiation Fibrosis (permanent lung tissue scarring in the treated radiation beam area)?
Scarring.

723. What is Radiation-Induced Cardiac Toxicity (pericarditis, coronary artery disease risk if radiation fields involve the heart)?
Cardiac damage.

724. How do modern IMRT and Proton plans strictly limit radiation dose to the heart (Mean Heart Dose <10 Gy)?
By conformal planning.

725. What is Radiation Esophageal Stricture (narrowing of esophagus months after treatment treated with dilation)?
Narrowing of the esophagus.

726. What is Rib Fracture risk after SBRT for chest wall tumors (~2–5% risk)?
Low risk.

727. What is Brachytherapy (Endobronchial Radiation)?
Radiation inside the airway.

728. How is high-dose catheter brachytherapy placed inside a blocked bronchus to open airways and stop bleeding?
Bronchoscopic placement.

729. How long does a daily standard radiation session take (typically 15 to 20 minutes total; beam delivery is 2 to 4 minutes)?
15–20 minutes.

730. Is radiation therapy painful while being delivered (no, completely invisible and painless like a standard X-ray)?
No.

731. Can a patient drive themselves to daily radiation appointments (yes, unless fatigued or taking sedating medications)?
Yes.

732. Can a patient continue working during 6 weeks of daily radiation therapy (many patients continue light/desk work)?
Many do.

733. What clothing should be worn to radiation appointments (loose, soft cotton clothing without metal buttons/zippers)?
Loose cotton clothing.

734. What skin care products are safe during radiation (Aquaphor, Miaderm, plain aloe; avoid heavy creams right before scan)?
Gentle moisturizers.

735. How do radiation oncologists use daily CT alignment (Cone-Beam CT) to verify millimeter accuracy before each beam delivery?
Daily imaging.

736. What tattoo dots or temporary skin marks guide daily patient setup?
Small tattoo dots.

737. Can tattoo-less surface-guided radiation therapy (SGRT) be used instead of permanent tattoos?
Yes.

738. What is the role of Radiation Therapy in Oligometastatic NSCLC (SABR-COMET trial protocol)?
SBRT to all metastatic sites.

739. How does delivering SBRT to all oligometastatic sites (1 to 5 metastatic lesions in brain, adrenal, bone, lung) extend overall survival?
It improves local control and survival.

740. What is Palliative Radiation for Bone Metastases (single 8 Gy fraction or 20 Gy in 5 fractions to relieve bone pain rapidly)?
Short-course radiation.

741. What is Radiation Therapy for Superior Vena Cava (SVC) obstruction or severe hemoptysis?
Palliative radiation.

742. What is the Abscopal Effect in radiation oncology?
A rare phenomenon where radiation shrinks distant tumors.

743. How can radiation to one tumor site occasionally stimulate an immune response that shrinks un-irradiated tumors elsewhere (especially when combined with immunotherapy)?
By releasing tumor antigens.

744. What skin care instructions apply during chest radiation (wash with warm water and mild soap, avoid hot tubs/swimming, protect from sun exposure)?
Gentle washing and sun protection.

745. How do dietitians assist patients experiencing radiation esophagitis (high-calorie liquid nutrition supplements, soft non-acidic foods)?
Soft, high-calorie foods.

746. What speech/swallowing therapy evaluates severe post-radiation dysphagia?
Swallowing therapy.

747. When should follow-up PET-CT or CT imaging be scheduled after radiation ends (typically 8 to 12 weeks post-radiation to allow acute inflammation to clear)?
8–12 weeks.

748. What is Radiation Pseudoprogression on follow-up CT (temporary inflammatory swelling that mimics tumor growth)?
Temporary enlargement.

749. What questions should you ask your radiation oncologist at your initial consultation?
Ask about technique, dose, and side effects.

750. “Am I receiving SBRT/SABR or conventional fractionated radiation?”
Correct.

751. “Is radiation being delivered concurrently with chemotherapy?”
Correct.

752. “What motion management (4D-CT / gating) will be used?”
Correct.

753. “What are the dose limits to my healthy lungs, heart, and esophagus?”
Correct.

754. “Am I eligible for consolidation Durvalumab immunotherapy after treatment?”
Correct.

755. How do radiation oncology nurses support patients daily through treatment side effects?
Symptom management.

756. What financial assistance grants help patients with travel costs for 6 weeks of daily radiation visits?
Patient assistance programs.

757. What non-profit lodging programs exist near major radiation treatment centers?
ACS Hope Lodge.

758. What clinical trials are testing flash radiation (ultra-high dose rate FLASH therapy) or novel radiosensitizers?
Ongoing trials.

759. How will AI-driven adaptive radiation therapy adjust treatment plans daily to match changing internal anatomy?
AI will refine targeting.

760. What summary message reinforces radiation safety and efficacy?
Modern radiation is precise and effective.

761. Modern targeted radiation (SBRT/IMRT/Proton) delivers powerful, precise tumor control while protecting healthy surrounding tissue.
Correct.

762. Report any new swallowing pain or dry cough early to your radiation team for prompt side-effect management.
Correct.

763. Maintain good hydration, eat soft high-protein foods, and rest when radiation fatigue occurs.
Correct.

764. Celebrate “ringing the bell” on your final day of radiation as a major milestone!
Correct.

765. Transition smoothly into consolidation immunotherapy or survivorship surveillance.
Correct.

766. Where can patients access radiation education guides from ASTRO (American Society for Radiation Oncology)?
ASTRO website.

767. How do peer support networks connect patients undergoing active daily chest radiation?
Support groups.

768. What step-by-step actions prepare you for your CT Simulation appointment?
Follow instructions and ask questions.

769. What digital health apps track daily radiation symptoms and hydration logs?
Symptom tracker apps.

770. What final reassurance empowers radiation candidates?
Radiation is safe and effective.

771. Precision radiation oncology has transformed Stage 3 and early-stage lung cancer care into highly manageable, curable treatments.
Correct.

772. Where can patients locate ASTRO-accredited radiation treatment centers near them?
ASTRO website.

773. What is proton beam therapy availability across regional cancer centers?
Limited but increasing.

774. How does radiation plan optimization spare spinal cord tissue (max dose <45–50 Gy)?
By treatment planning.

775. How does SBRT re-irradiation work for recurrent lung lesions?
High-precision repeat radiation.

776. What is the role of palliative radiotherapy in controlling bronchial bleeding?
It stops bleeding.

777. What pre-treatment dental clearance is needed if head/neck radiation fields overlap?
Dental evaluation.

778. How do custom immobilization vacuum cushions hold patients still during lung SBRT?
They immobilize the patient.

779. What post-radiation scar tissue changes appear on follow-up chest imaging?
Fibrosis and scarring.

780. What final checklist prepares you for your first radiation treatment session?
Follow instructions and ask questions.

781. What systemic drug therapies treat NSCLC?
Chemotherapy, immunotherapy, and targeted therapy.

782. What are the three main classes of systemic cancer drugs (Chemotherapy, Immunotherapy, Targeted Therapy)?
Correct.

783. What is Systemic Chemotherapy for NSCLC?
Cytotoxic drugs.

784. How does cytotoxic chemotherapy work (kills rapidly dividing cells throughout the body)?
It interferes with cell division.

785. What is Platinum-Doublet Chemotherapy (the foundation chemotherapy regimen for NSCLC)?
A platinum drug plus a second agent.

786. What Platinum drugs are used (Cisplatin or Carboplatin)?
Cisplatin or carboplatin.

787. What partner drugs are combined with Platinum agents for Non-Squamous NSCLC (Pemetrexed / Alimta)?
Pemetrexed.

788. What partner drugs are combined with Platinum agents for Squamous Cell NSCLC (Paclitaxel, Docetaxel, or Gemcitabine)?
Paclitaxel, docetaxel, or gemcitabine.

789. How many cycles of first-line platinum-doublet chemo are given (typically 4 cycles every 3 weeks)?
4 cycles.

790. What is Maintenance Chemotherapy (e.g., single-agent Pemetrexed maintenance for non-squamous NSCLC)?
Continued single-agent chemotherapy.

791. What are common side effects of platinum chemotherapy (hair loss, nausea, fatigue, low blood counts, neuropathy, kidney changes, metallic taste)?
These are common.

792. How is chemotherapy nausea prevented with modern antiemetic drugs (NK-1 inhibitors, 5-HT3 antagonists, dexamethasone, olanzapine)?
Combination antiemetics.

793. What is neutropenia, and how do G-CSF growth factor injections (Neulasta, Udenyca) prevent neutropenic fever?
Low white blood cell count; G-CSF stimulates production.

794. What is chemotherapy-induced peripheral neuropathy (CIPN), and how is it managed?
Nerve damage; managed with dose reduction.

795. What is Immunotherapy (Immune Checkpoint Inhibitors) for NSCLC?
Drugs that unleash the immune system.

796. How do immune checkpoint inhibitors work (unmask cancer cells by blocking PD-1/PD-L1 or CTLA-4 proteins, enabling T-cells to destroy the tumor)?
They block inhibitory signals.

797. What Anti-PD-1 Immunotherapy drugs are approved for NSCLC?
Pembrolizumab, nivolumab, cemiplimab.

798. Pembrolizumab (Keytruda).
Correct.

799. Nivolumab (Opdivo).
Correct.

800. Cemiplimab (Libtayo).
Correct.

801. What Anti-PD-L1 Immunotherapy drugs are approved for NSCLC?
Atezolizumab, durvalumab.

802. Atezolizumab (Tecentriq).
Correct.

803. Durvalumab (Imfinzi).
Correct.

804. What Anti-CTLA-4 Immunotherapy drugs are approved for NSCLC?
Ipilimumab, tremelimumab.

805. Ipilimumab (Yervoy).
Correct.

806. Tremelimumab (Imjudo).
Correct.

807. What is Bispecific PD-1/VEGF Immunotherapy (Ivonescimab) in advanced NSCLC?
A bispecific antibody targeting PD-1 and VEGF.

808. How is Immunotherapy selected based on PD-L1 expression levels in NSCLC?
PD-L1 ≥50%: single-agent immunotherapy; lower levels: chemo-immunotherapy.

809. If PD-L1 TPS ≥50% (and no EGFR/ALK mutations): First-line single-agent Immunotherapy (e.g., Pembrolizumab alone) OR chemo-immunotherapy.
Correct.

810. If PD-L1 TPS 1–49% or <1%: First-line Chemo-Immunotherapy combination (e.g., Keytruda + Carboplatin + Pemetrexed).
Correct.

811. How is Immunotherapy administered (IV infusion every 2, 3, 4, or 6 weeks)?
Intravenous infusion.

812. How long does Immunotherapy treatment last for advanced NSCLC (typically up to 2 years if disease remains controlled)?
Up to 2 years.

813. What are Immune-Related Adverse Events (irAEs) from Immunotherapy?
Autoimmune side effects.

814. Why do irAEs occur (overactive immune system attacks healthy organs)?
Immune activation against normal tissues.

815. What organs can be affected by irAEs (lungs/pneumonitis, colon/colitis, liver/hepatitis, skin/rash, thyroid/thyroiditis, pituitary/hypophysitis, heart/myocarditis)?
These organs.

816. What is Immune Checkpoint Inhibitor Pneumonitis (cough, shortness of breath, low oxygen)?
Lung inflammation.

817. How are irAEs treated (holding immunotherapy + systemic corticosteroids e.g. Prednisone/Solu-Medrol, immunosuppressants e.g. Infliximab if severe)?
Corticosteroids and immunosuppressants.

818. Why is early recognition of irAEs critical for patient safety?
Early treatment prevents severe complications.

819. What is Targeted Therapy (Tyrosine Kinase Inhibitors / TKIs) for NSCLC?
Oral drugs that block specific mutant proteins.

820. How do TKIs work (orally swallowed daily pills that directly block specific mutated proteins driving cancer growth)?
They inhibit mutant kinases.

821. What Targeted Therapies treat EGFR-Mutated NSCLC?
Osimertinib, amivantamab/lazertinib, erlotinib, gefitinib, afatinib, dacomitinib.

822. 3rd-Generation EGFR TKI: Osimertinib (Tagrisso) – gold standard first-line treatment.
Correct.

823. EGFR + MET Combination: Amivantamab (Rybrevant) + Lazertinib (Lazcluze).
Correct.

824. 1st/2nd-Gen EGFR TKIs: Erlotinib, Gefitinib, Afatinib, Dacomitinib.
Correct.

825. What Targeted Therapies treat EGFR Exon 20 Insertion Mutations (Amivantamab + Chemo, Sunvozertinib)?
Amivantamab and sunvozertinib.

826. What Targeted Therapies treat ALK-Rearranged NSCLC?
Lorlatinib, alectinib, brigatinib.

827. 3rd-Generation ALK TKIs: Lorlatinib (Lorbrena) – CROWN trial (unprecedented 5-year progression-free survival >60%), Alectinib (Alecensaro), Brigatinib (Alunbrig).
Correct.

828. What Targeted Therapies treat KRAS G12C-Mutated NSCLC (Sotorasib / Lumakras, Adagrasib / Krazati)?
Sotorasib, adagrasib.

829. What are pan-KRAS / RAS(ON) inhibitors targeting broad KRAS mutations (Daraxonrasib)?
Investigational pan-KRAS inhibitors.

830. What Targeted Therapies treat ROS1-Rearranged NSCLC (Repotrectinib / Augtyro, Entrectinib, Crizotinib)?
Repotrectinib, entrectinib, crizotinib.

831. What Targeted Therapies treat BRAF V600E-Mutated NSCLC (Dabrafenib + Trametinib, Encorafenib + Binimetinib)?
Dabrafenib/trametinib, encorafenib/binimetinib.

832. What Targeted Therapies treat MET Exon 14 Skipping NSCLC (Capmatinib / Tabrecta, Tepotinib / Tepmetko)?
Capmatinib, tepotinib.

833. What Targeted Therapies treat RET Fusion-Positive NSCLC (Selpercatinib / Retevmo, Pralsetinib / Gavreto)?
Selpercatinib, pralsetinib.

834. What Targeted Therapies treat NTRK Fusion-Positive NSCLC (Larotrectinib / Vitrakvi, Entrectinib / Rozlytrek)?
Larotrectinib, entrectinib.

835. What Targeted Therapies treat HER2-Mutated NSCLC (Sevabertinib, Fam-Trastuzumab Deruxtecan / Enhertu)?
Sevabertinib, trastuzumab deruxtecan.

836. What are Antibody-Drug Conjugates (ADCs) in NSCLC?
Monoclonal antibodies linked to cytotoxic drugs.

837. How do ADCs work (“smart bombs” attaching a targeted monoclonal antibody to a potent chemotherapy payload)?
They deliver chemotherapy directly to cancer cells.

838. What ADCs are approved or in advanced trials for NSCLC (Trastuzumab Deruxtecan / Enhertu, Datopotamab Deruxtecan / Dato-DXd, Telisotuzumab Vedotin / Teliso-V)?
These are in use or trials.

839. What are common side effects of EGFR TKIs (Osimertinib) (diarrhea, acneiform skin rash, dry skin, paronychia/nail infection, fatigue)?
These are common.

840. What are common side effects of ALK TKIs (Alectinib/Lorlatinib) (fatigue, weight gain, elevated cholesterol/triglycerides, cognitive/mood shifts with Lorlatinib, edema)?
These are common.

841. How do daily oral TKI pills offer vastly superior quality of life compared to traditional chemotherapy?
They are oral, targeted, and better tolerated.

842. What is Targeted Therapy Drug Resistance?
Cancer cells develop mechanisms to bypass the drug.

843. Why do cancer cells eventually develop secondary mutations that make them resistant to targeted TKI pills?
Genetic evolution under drug pressure.

844. How is drug resistance detected (repeat tissue biopsy or liquid biopsy ctDNA testing at time of progression)?
Repeat biopsy or liquid biopsy.

845. What treatment strategies follow TKI resistance (switching TKI generations, adding chemo, ADC therapy, or clinical trial combinations)?
Switch TKI, add chemo, use ADCs, or trials.

846. How are brain metastases managed in EGFR+ or ALK+ NSCLC?
CNS-penetrant TKIs, SRS, or surgery.

847. Modern 3rd-generation TKIs (Osimertinib, Lorlatinib, Alectinib) have exceptional blood-brain barrier penetration, often shrinking brain metastases without needing radiation!
Correct.

848. What is Anti-Angiogenic Therapy (Bevacizumab / Avastin, Ramucirumab / Cyramza)?
Drugs that block blood vessel growth.

849. How do anti-angiogenic drugs block VEGF blood vessel formation feeding the tumor?
They inhibit VEGF signaling.

850. Why is Bevacizumab avoided in Squamous Cell Carcinoma (risk of severe pulmonary hemorrhage)?
Due to bleeding risk.

851. What second-line Chemotherapy options exist for relapsed NSCLC (Docetaxel +/- Ramucirumab, Gemcitabine)?
Docetaxel ± ramucirumab, gemcitabine.

852. How is systemic treatment tailored for elderly or frail patients (single-agent chemo, dose reductions, gentle oral TKIs)?
Dose reduction and single agents.

853. What blood monitoring is required during active chemo/immunotherapy/TKI treatments?
CBC, CMP, LFTs.

854. How do oncology infusion nurses manage IV drug delivery safely through chemo ports?
Sterile technique and monitoring.

855. What dental clearance is required before starting bone-modifying drugs (Zoledronic acid / Zometa, Denosumab / Xgeva)?
Dental exam.

856. Why is osteonecrosis of the jaw (ONJ) a rare risk of bone-targeted therapies?
It can impair jaw healing.

857. How do patients store and take oral targeted TKI pills safely at home (taking pills at same time daily, handling instructions, avoiding missed doses)?
Take at same time daily.

858. What food or drug interactions must be avoided with oral TKIs (grapefruit juice, St. John’s Wort, strong CYP3A4 inhibitors/inducers, PPI antacids)?
Avoid grapefruit, St. John’s Wort, and interacting drugs.

859. How do specialty pharmacies deliver oral TKI medications directly to patient homes?
Mail delivery.

860. How do financial navigation programs help patients afford expensive monthly oral TKI co-pays (copay assistance cards, foundation grants)?
Copay cards and grants.

861. What clinical trial databases (ClinicalTrials.gov, LUNGevity Clinical Trial Finder) match patients with novel drug studies?
ClinicalTrials.gov and LUNGevity.

862. What questions should you ask your medical oncologist before starting systemic treatment?
Ask about biomarkers, drug choice, side effects, and goals.

863. “What are my exact biomarker / NGS mutation results and PD-L1 score?”
Correct.

864. “Is an oral Targeted Therapy, Immunotherapy, or Chemo combination recommended?”
Correct.

865. “What are the expected side effects, and how will we manage them?”
Correct.

866. “What is the goal of this treatment (curative intent vs long-term disease control)?”
Correct.

867. “Are there open clinical trials I should consider?”
Correct.

868. How do multidisciplinary care teams support long-term drug adherence and symptom control?
Through coordinated care.

869. What summary message reflects modern systemic NSCLC care?
Precision medicine has transformed outcomes.

870. Precision medicine—matching the right drug to the right tumor gene mutation—has transformed advanced NSCLC into a highly manageable condition with unprecedented long-term survival.
Correct.

871. How are mRNA cancer vaccines (e.g., BNT116) being evaluated in early and advanced NSCLC?
In clinical trials.

872. What is the role of tumor-infiltrating lymphocyte (TIL) cell therapy in relapsed NSCLC?
Investigational.

873. What is bispecific antibody therapy (e.g., targeting MET and EGFR simultaneously)?
Investigational bispecific antibodies.

874. How do oncologists manage dermatologic side effects (paronychia, rash) from EGFR inhibitors?
Topical treatments and dose adjustments.

875. What routine cardiac monitoring (Echocardiogram / ECG) is required during TKI or ADC therapy?
Regular monitoring.

876. How does liver function (ALT/AST) monitoring guide TKI dose holds and adjustments?
Regular LFT monitoring.

877. What is the role of steroid pre-medication before Pemetrexed chemotherapy (Folic Acid + B12 + Dexamethasone to prevent severe toxicity)?
It prevents severe toxicity.

878. Why is Vitamin B12 and Folic Acid supplementation mandatory starting prior to Pemetrexed infusion?
To prevent toxicity.

879. How long after completing systemic therapy does physical strength and hair growth return?
Gradually over weeks to months.

880. What final reassurance empowers patients starting systemic therapy (modern targeted drugs have turned oncogene-addicted NSCLC into a treatable, chronic-like condition)?
Modern drugs have transformed outcomes.

881. What is Stage 4 (Metastatic) NSCLC?
Cancer that has spread to distant organs.

882. What does “metastatic” mean (cancer cells have detached from the primary lung tumor and traveled through blood/lymph to form new tumors elsewhere)?
Spread to distant sites.

883. What are the most common sites of distant metastasis in NSCLC (brain, bones, adrenal glands, liver, opposite lung, distant lymph nodes)?
These sites.

884. Is Stage 4 NSCLC curable?
Generally not curable, but long-term remissions are increasingly achieved.

885. Stage 4 NSCLC is generally considered treatable but not traditionally curable, though long-term durable remissions (>5–10+ years) are increasingly achieved with modern targeted therapies and immunotherapies.
Correct.

886. What is Oligometastatic NSCLC?
Limited metastatic spread (1–5 lesions).

887. What defines oligometastatic disease (limited metastatic spread: typically 1 to 5 total metastatic lesions in 1 or 2 organs)?
1–5 lesions in 1–2 organs.

888. How is oligometastatic NSCLC treated aggressively (combining systemic therapy + local ablative treatment like SBRT or surgery to ALL tumor sites)?
Systemic therapy plus local ablation.

889. What did landmark trials (SABR-COMET, Gomez et al.) prove about aggressive local treatment for oligometastatic NSCLC (significantly doubles progression-free and overall survival)?
It improves survival.

890. What is Oligoprogressing NSCLC?
Progression in a few sites while others remain controlled.

891. How is oligoprogressing disease managed (continuing systemic TKI/immunotherapy while delivering local SBRT radiation strictly to the single progressing lesion)?
Continue systemic therapy and add local SBRT.

892. How are Brain Metastases from NSCLC managed?
SRS, surgery, WBRT, and CNS-penetrant TKIs.

893. Local treatments: Stereotactic Radiosurgery (SRS / Gamma Knife), Surgical Resection (for single large symptomatic brain mass), Whole-Brain Radiation (WBRT).
Correct.

894. Systemic treatments: High CNS-penetration targeted TKIs (Osimertinib, Lorlatinib, Alectinib, Repotrectinib).
Correct.

895. What is Leptomeningeal Disease (LMD / carcinomatous meningitis)?
Spread to the leptomeninges.

896. What causes LMD (cancer cells spreading into the fluid-filled membranes surrounding the brain and spinal cord)?
Cancer cells in CSF.

897. How is LMD diagnosed (Brain/Spine MRI + Lumbar Puncture CSF cytology)?
MRI and CSF cytology.

898. How is LMD treated (high-dose CNS-penetrating TKIs, intrathecal chemotherapy, proton beam radiation)?
CNS-penetrant TKIs, intrathecal chemo, radiation.

899. How are Bone Metastases managed?
Bone-modifying agents and local radiation.

900. Systemic treatments: Bone-modifying agents (Zoledronic acid / Zometa IV every 1–3 months, Denosumab / Xgeva subcutaneous injection monthly).
Correct.

901. How do bone-modifying agents prevent Skeletal-Related Events (SREs – fractures, bone pain, spinal cord compression, hypercalcemia)?
They reduce bone resorption.

902. Local treatments: Palliative SBRT or single-fraction radiation for localized bone pain, orthopedic stabilization surgery for unstable long bones.
Correct.

903. What is Spinal Cord Compression from vertebral bone metastasis?
Tumor pressing on the spinal cord.

904. Why is spinal cord compression a medical emergency requiring immediate high-dose IV steroids (Dexamethasone) + emergency SRS/surgery within 24 hours?
Delay can cause paralysis.

905. How are Adrenal Metastases managed (systemic therapy + SBRT or adrenalectomy if solitary)?
Systemic therapy plus local ablation.

906. How are Liver Metastases managed (systemic therapy + SBRT or chemoembolization if oligometastatic)?
Systemic therapy plus local ablation.

907. What is Malignant Pleural Effusion (MPE) management?
Thoracentesis, indwelling catheter, or pleurodesis.

908. What is a Thoracentesis (draining pleural fluid using a needle for temporary relief)?
Needle drainage.

909. What is a PleurX / Indwelling Pleural Catheter (IPC)?
A catheter for home drainage.

910. How does a PleurX catheter allow patients or family to drain pleural fluid comfortably at home 2 to 3 times weekly?
Home drainage.

911. What is Pleurodesis (chemical fusion of visceral and parietal pleura using talc slurry or doxycycline to permanently prevent fluid re-accumulation)?
Chemical fusion.

912. What is Malignant Pericardial Effusion management?
Pericardiocentesis or pericardial window.

913. What is a Pericardial Window / Pericardiocentesis (draining fluid around the heart to prevent cardiac tamponade)?
Drainage.

914. What is Palliative Care in NSCLC?
Care to relieve symptoms and improve quality of life.

915. Is Palliative Care the same as End-of-Life Hospice Care?
No; palliative care can be given alongside active treatment.

916. Fact: Palliative Care is specialized medical care focused on relieving symptoms, pain, and stress at ANY stage of disease, delivered CONCURRENTLY alongside active cancer treatments.
Correct.

917. What did Temel et al. landmark study prove about Early Palliative Care in metastatic NSCLC?
It improves quality of life and may extend survival.

918. Integrating palliative care within 8 weeks of Stage 4 diagnosis improves quality of life, reduces depression, avoids futile aggressive end-of-life care, AND extends median overall survival by ~3 months!
Correct.

919. What symptoms are managed by a Palliative Care team?
Dyspnea, pain, nausea, fatigue, anorexia, anxiety, depression, and sleep disturbance.

920. How is severe dyspnea managed in advanced NSCLC (low-dose opioids e.g. liquid Morphine, supplemental oxygen, handheld fan blowing cool air on face, positioning)?
Low-dose opioids, oxygen, and fan therapy.

921. How is Cancer Pain managed (WHO Pain Ladder: Acetaminophen/NSAIDs → Mild Opioids → Strong Opioids like Morphine, Oxycodone, Fentanyl, Methadone)?
Stepwise analgesia.

922. How is Neuropathic Pain managed (Gabapentin, Pregabalin, Duloxetine)?
Neuropathic agents.

923. How is Cancer Cachexia (severe muscle wasting and weight loss) managed?
Nutritional support and appetite stimulants.

924. High-protein nutritional supplements, Megestrol acetate / Medroxyprogesterone, low-dose steroids, ghrelin receptor agonists (Anamorelin).
Correct.

925. How is severe fatigue managed (energy conservation strategies, gentle walking, short daytime naps, psychostimulants like Methylphenidate / Modafinil)?
Energy conservation and psychostimulants.

926. What is an Advanced Directive?
Legal documents stating healthcare preferences.

927. What key documents complete an Advanced Directive?
Living will, healthcare power of attorney, DNR/DNI, POLST.

928. Living Will (specifying medical care preferences).
Correct.

929. Durable Power of Attorney for Healthcare / Healthcare Proxy (designating trusted decision-maker).
Correct.

930. DNR (Do Not Resuscitate) / DNI (Do Not Intubate) orders.
Correct.

931. POLST / MOLST (Physician Orders for Life-Sustaining Treatment).
Correct.

932. Why should advanced care planning conversations happen early after a Stage 4 diagnosis?
To ensure wishes are respected.

933. What is Hospice Care?
Comfort-focused care for patients with limited life expectancy.

934. When is Hospice Care appropriate (when cancer treatments no longer control disease, life expectancy is estimated at 6 months or less, and focus shifts entirely to comfort and quality of life)?
When life expectancy is ≤6 months.

935. Where is Hospice Care delivered (home, inpatient hospice facility, nursing home, hospital hospice unit)?
Home, inpatient facility, nursing home, or hospital unit.

936. What services are provided by a Hospice interdisciplinary team (physician, hospice nurse, social worker, chaplain, home health aide, bereavement counselor)?
Medical, nursing, psychosocial, spiritual, and bereavement care.

937. How does Medicare Hospice Benefit cover 100% of hospice medications, durable medical equipment e.g. hospital bed/oxygen, and caregiver respite?
It covers medications, equipment, and respite.

938. What is Respite Care for family caregivers?
Short-term relief for caregivers.

939. What physical signs indicate that a terminal NSCLC patient is entering the final actively dying phase (24 to 72 hours)?
Weakness, altered breathing, terminal congestion, mottled extremities, decreased urine output.

940. Physical signs: Profound weakness/unresponsiveness, altered breathing patterns (Cheyne-Stokes respiration), terminal congestion (“death rattle”), cool mottled extremities, decreased urine output.
Correct.

941. How is terminal congestion (“death rattle”) managed (anticholinergic medications e.g. Sublingual Atropine drops, Glycopyrrolate, positioning on side)?
Anticholinergics and repositioning.

942. How do hospice nurses ensure pain-free, dignified end-of-life care?
Through symptom management.

943. How does bereavement counseling support grieving family members for up to 13 months following a patient’s death?
Emotional support.

944. How do oncology social workers assist with disability benefits (SSDI / Compassionate Allowance Program for fast-track approval)?
They help with applications.

945. What is the Social Security Compassionate Allowances program for NSCLC?
Fast-tracks SSDI for qualifying stage IV NSCLC.

946. Fast-tracks SSDI disability application approval within weeks for Stage 4 NSCLC.
Correct.

947. What financial assistance programs help metastatic patients manage housing, utilities, and co-pays (PAN Foundation, HealthWell, CancerCare)?
PAN Foundation, HealthWell, CancerCare.

948. How can patients access free transportation services to cancer treatment (ACS Road To Recovery program)?
ACS Road to Recovery.

949. What support organizations connect Stage 4 NSCLC patients with peer mentors (LUNGevity Peer-to-Peer, GO2 for Lung Cancer Phone Buddy)?
LUNGevity and GO2.

950. How do virtual telehealth visits allow frail metastatic patients to consult with care teams without traveling?
Remote consultations.

951. What follow-up surveillance schedule is required after curative-intent NSCLC treatment?
Chest CT every 3–6 months for 2–3 years, then every 6–12 months to 5 years, then annually.

952. Chest CT scan every 3 to 6 months for the first 2 to 3 years, then every 6 to 12 months up to 5 years, then annual screening CT indefinitely.
Correct.

953. What is “Scanxiety” (severe anxiety and dread preceding routine follow-up CT/PET scans)?
Anxiety before surveillance scans.

954. How can survivors manage scanxiety (mindfulness, CBT, scheduling scans early in week, bringing support person, prompt result delivery)?
Mindfulness, CBT, and support.

955. What is a written Survivorship Care Plan?
A document summarizing treatment and follow-up recommendations.

956. What details belong in your Survivorship Care Plan (exact histology, TNM stage, NGS mutations, treatment history, follow-up scan schedule, side-effect care, care team contacts)?
All relevant details.

957. What key documents should be organized in a personal “NSCLC Health Binder”?
Pathology, biomarker results, imaging, treatment summaries, and insurance records.

958. Pathology report, NGS biomarker results, surgical notes, scan discs/reports, treatment summaries, insurance pre-authorizations.
Correct.

959. What digital health apps help manage appointment schedules, medication reminders, and scan dates?
Medication and appointment reminder apps.

960. How do second opinions at NCI-designated Comprehensive Cancer Centers empower survivors?
Expert review.

961. How can survivors participate in lung cancer research registries and tissue biobanks?
By enrolling through cancer centers.

962. What annual awareness events honor lung cancer survivors (Lung Cancer Awareness Month in November)?
Lung Cancer Awareness Month in November.

963. What evidence-based books provide guidance on navigating lung cancer (e.g., A Cure Within by Neil Canavan, A Breath of Hope)?
A Cure Within and similar books.

964. How does mindfulness meditation improve sleep quality and lower physiological stress in survivors?
Reduces stress.

965. What role do oncology social workers play in supporting survivors and families?
Counseling and resource navigation.

966. What key questions should every survivor ask at their routine follow-up visits?
Ask about scan schedule, late effects, and rehab.

967. “Is my follow-up chest CT scan up to date?”
Correct.

968. “Are there any late side effects we should monitor?”
Correct.

969. “What pulmonary rehab or physical therapy resources can help my breathing?”
Correct.

970. How does staying informed transform health anxiety into proactive, confident wellness management?
Knowledge reduces fear.

971. What is the single most inspiring message for anyone living with an NSCLC diagnosis?
Scientific breakthroughs are helping many people live long, high-quality lives.

972. You are not a statistic: scientific breakthroughs in precision targeted drugs, immunotherapies, and robotic surgeries are helping thousands of people live long, vibrant, high-quality lives with NSCLC today.
Correct.

973. What immediate steps should a newly diagnosed NSCLC patient take today?
Gather records, ensure biomarker testing, seek expert second opinion, and connect with support.

974. Step 1: Obtain printed copies of your pathology report, NGS biomarker results, and scan reports.
Correct.

975. Step 2: Ensure broad NGS genomic testing and PD-L1 testing have been ordered.
Correct.

976. Step 3: Seek a second opinion from a dedicated Thoracic Medical Oncologist at an NCI-designated Comprehensive Cancer Center.
Correct.

977. Step 4: Connect with a biomarker-specific patient advocacy group (e.g., EGFR Resisters, ALK Positive, LUNGevity) for peer support.
Correct.

978. Take charge of your lung health journey today—expert medicine, cutting-edge science, and a compassionate global community stand ready to support you every step of the way!
Correct.

979. What is the most important message about NSCLC survivorship?
Survivorship is lifelong, with surveillance, support, and healthy habits.

980. Why is long-term follow-up important after curative treatment?
To detect recurrence and new primary cancers early.

981. What should a survivor do if they notice new symptoms between visits?
Contact their oncology team promptly.

982. What is the final takeaway about NSCLC?
Prevention, early detection, precision treatment, and supportive care can substantially improve outcomes and quality of life.